<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96414</article-id><article-id pub-id-type="doi">10.7554/eLife.96414</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The human cytomegalovirus-encoded pUS28 antagonizes CD4+ T cell recognition by targeting CIITA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maassen</surname><given-names>Fabienne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0004-3535-3727</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Le-Trilling</surname><given-names>Vu Thuy Khanh</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2733-3732</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Betke</surname><given-names>Luisa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-6767-6239</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bracht</surname><given-names>Thilo</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Siegmund</surname><given-names>Corinna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1371-0779</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bayer</surname><given-names>Malte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1060-8856</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Katschinski</surname><given-names>Benjamin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1314-2820</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Belter</surname><given-names>Antonia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0005-4409-1447</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Becker</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mennerich</surname><given-names>Denise</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Voigt</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Frappier</surname><given-names>Lori</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sitek</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Fleischhauer</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Trilling</surname><given-names>Mirko</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3659-3541</contrib-id><email>mirko.trilling@uni-due.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mz5ra38</institution-id><institution>Institute for Virology, University Hospital Essen, University of Duisburg-Essen</institution></institution-wrap><addr-line><named-content content-type="city">Essen</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mz5ra38</institution-id><institution>Institute for Experimental Cellular Therapy, University Hospital Essen, University of Duisburg-Essen</institution></institution-wrap><addr-line><named-content content-type="city">Essen</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mz5ra38</institution-id><institution>Institute for the Research on HIV and AIDS‐associated Diseases, University Hospital Essen, University of Duisburg-Essen</institution></institution-wrap><addr-line><named-content content-type="city">Essen</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tsk2644</institution-id><institution>Medizinisches Proteom Center, Ruhr University Bochum</institution></institution-wrap><addr-line><named-content content-type="city">Bochum</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024j3hn90</institution-id><institution>Department of Anesthesia, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum</institution></institution-wrap><addr-line><named-content content-type="city">Bochum</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03dbr7087</institution-id><institution>Department of Molecular Genetics, University of Toronto</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pqn3g31</institution-id><institution>German Cancer Consortium (DKTK), partner site Essen/Düsseldorf</institution></institution-wrap><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Brune</surname><given-names>Wolfram</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r2q1d96</institution-id><institution>Leibniz Institute of Virology (LIV)</institution></institution-wrap><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>The University of Tokyo</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>07</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e96414</elocation-id><history><date date-type="received" iso-8601-date="2024-01-25"><day>25</day><month>01</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-06-02"><day>02</day><month>06</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-10-19"><day>19</day><month>10</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.10.17.562683"/></event></pub-history><permissions><copyright-statement>© 2025, Maassen et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Maassen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96414-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96414-figures-v1.pdf"/><abstract><p>Human cytomegalovirus (HCMV) is a relevant pathogen, especially for individuals with impaired immunity. Harnessing potent immune antagonists, HCMV circumvents sterile immunity. Given that HCMV prevents the upregulation of <italic>human leukocyte antigen</italic> (HLA)-DP and HLA-DR, we screened a library of HCMV genes by co-expression with the HLA class II (HLA-II)-inducing transcription coordinator <italic>class II transactivator</italic> (CIITA). We identified the latency regulator pUS28 as an interaction factor and potent viral antagonist of CIITA-driven expression of CD74, HLA-DR, HLA-DM, HLA-DQ, and HLA-DP. Both wt-pUS28 and a mutant incapable of inducing G protein-coupled signaling (R129A), but not a mutant lacking the C-terminus, drastically reduced the CIITA protein abundance post-transcriptionally. While control CD4 + T cells from HCMV-seropositive individuals vigorously responded to CIITA-expressing cells decorated with HCMV antigens, pUS28 expression was sufficient to inhibit HLA-II induction and immune recognition by HCMV-specific CD4 + T cells. Our data uncover pUS28 to be employed by HCMV to evade HLA-II-mediated recognition by CD4 + T cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Human cytomegalovirus</kwd><kwd>HCMV</kwd><kwd>human herpesvirus 5</kwd><kwd>HHV-5</kwd><kwd>US28</kwd><kwd>HLA class II</kwd><kwd>CIITA</kwd><kwd>CD4+ T cells</kwd><kwd>CD74</kwd><kwd>M33</kwd><kwd>G protein-coupled receptor</kwd><kwd>GPCR</kwd><kwd>HLA-DR</kwd><kwd>HLA-DP</kwd><kwd>latency</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>TR 1208/1-1</award-id><principal-award-recipient><name><surname>Trilling</surname><given-names>Mirko</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>TR 1208/2-1</award-id><principal-award-recipient><name><surname>Trilling</surname><given-names>Mirko</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>FL 843/1-1</award-id><principal-award-recipient><name><surname>Fleischhauer</surname><given-names>Katharina</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005677</institution-id><institution>Deutsche Jose Carreras Leukämie Stiftung</institution></institution-wrap></funding-source><award-id>DJCLS 20R/2019</award-id><principal-award-recipient><name><surname>Fleischhauer</surname><given-names>Katharina</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004426</institution-id><institution>Dr. Werner Jackstädt-Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fleischhauer</surname><given-names>Katharina</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Joseph Senker Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fleischhauer</surname><given-names>Katharina</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Through the destabilization of CIITA, the human cytomegalovirus-encoded protein pUS28 antagonizes the expression of the HLA-II molecules CD74/Ii, HLA-DR, HLA-DQ, HLA-DM, and HLA-DP, diminishing the activation of HCMV-specific CD4+ T cells and reducing their secretion of antiviral cytokines.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>More than half of the entire adult human population and over 90% of the elderly in developing countries are latently infected with the human cytomegalovirus (HCMV, human betaherpesvirus 5 [HHV-5]; NCBI taxonomy ID 10359) (<xref ref-type="bibr" rid="bib26">Fowler et al., 2022</xref>). In healthy adults, HCMV raises strong canonical as well as non-canonical immune responses that limit viral replication and, in the vast majority of cases, prevent overt clinical manifestations, while leaving a substantial footprint on the immune system. Accordingly, more than half of all immune parameters are altered in HCMV-infected individuals (<xref ref-type="bibr" rid="bib11">Brodin et al., 2015</xref>). Equipped with an astonishing arsenal of highly potent immune evasins, HCMV circumvents sterile immunity and instead establishes a life-long latency from which it reactivates during episodes of stress or impaired immunity. In cases of immune immaturity, immune senescence, or impairment of the immune system, HCMV replication is not properly controlled, frequently resulting in severe morbidity and mortality in patients such as congenitally infected infants, people living with HIV, and transplant recipients (<xref ref-type="bibr" rid="bib34">Griffiths and Reeves, 2021</xref>).</p><p>Although the concerted activity of various mediators of innate and adaptive immunity is crucial for efficient cytomegalovirus (CMV) control (<xref ref-type="bibr" rid="bib73">Polić et al., 1998</xref>), two aspects are particularly important: interferon (IFN) responses and CD4 + T cells. Accordingly, the depletion of CD4 + cells together with IFNγ results in CMV reactivation in more than 75% of animals (<xref ref-type="bibr" rid="bib73">Polić et al., 1998</xref>). IFN secretion is among the first responses elicited upon pathogen encounter. IFNs trigger signaling cascades and initiate a specific transcriptional profile that fosters intrinsic immunity, induces direct innate immunity, and orchestrates adaptive immune responses. In this regard, IFNs act by inducing IFN-stimulated genes (ISGs), many of which are known for their antiviral activity, and by downregulating IFN-repressed genes (IRepGs) (<xref ref-type="bibr" rid="bib63">Megger et al., 2017</xref>; <xref ref-type="bibr" rid="bib78">Schoggins et al., 2011</xref>; <xref ref-type="bibr" rid="bib93">Trilling et al., 2013</xref>). In addition to their ability to establish a cell-intrinsic antiviral state, IFNs boost adaptive immune responses. In particular, IFNγ is well known as a key cytokine for antiviral Th1 responses and as potent enhancer of antigen presentation. In accordance with the relevance of IFNs, the absence of IFN-induced signaling renders mice extremely vulnerable to CMV infections (<xref ref-type="bibr" rid="bib32">Gil et al., 2001</xref>; <xref ref-type="bibr" rid="bib58">Le Trilling et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Strobl et al., 2005</xref>). CMV infection induces strong CD4 + T cell responses. While best known for their cytokine secretion, helping B cells and CD8 + T cells, CD4 + T cells can elicit antiviral activity (<xref ref-type="bibr" rid="bib41">Jonjić et al., 1990</xref>; <xref ref-type="bibr" rid="bib60">Lim et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Verma et al., 2016</xref>). The latter is associated with the ability to secrete antiviral cytokines such as IFNγ. Furthermore, certain CD4 + T cells can kill virus-infected cells (<xref ref-type="bibr" rid="bib42">Juno et al., 2017</xref>). HCMV-specific CD4 + T cells were shown to produce IFNγ, TNFα, and granzyme B (<xref ref-type="bibr" rid="bib28">Gamadia et al., 2004</xref>) and to lyse HCMV antigen-expressing cells in vitro (<xref ref-type="bibr" rid="bib95">van Leeuwen et al., 2006</xref>; <xref ref-type="bibr" rid="bib94">van Leeuwen et al., 2004</xref>). Accordingly, CD4 + T cell-mediated immunity is crucial for CMV control in mouse models in vivo (<xref ref-type="bibr" rid="bib40">Jonjić et al., 1989</xref>; <xref ref-type="bibr" rid="bib41">Jonjić et al., 1990</xref>; <xref ref-type="bibr" rid="bib100">Walton et al., 2008</xref>), and for controlling maternal viremia and preventing severe CMV-associated fetal disease during primary rhesus CMV infections (<xref ref-type="bibr" rid="bib6">Bialas et al., 2015</xref>). Furthermore, CD4 + T cells are fundamental to prevent HCMV reactivation in immunocompromised patients receiving solid organ allografts (<xref ref-type="bibr" rid="bib60">Lim et al., 2020</xref>) or hematopoietic cell transplantation (HCT), while insufficient CD4 + T cell levels in transplant recipients are associated with recurrent HCMV reactivation, end-organ disease, and an increased likelihood of lethal infections (<xref ref-type="bibr" rid="bib21">Einsele et al., 1993</xref>; <xref ref-type="bibr" rid="bib27">Gabanti et al., 2015</xref>).</p><p>For the canonical T cell receptor (TCR)-dependent activation of CD4 + T cells, antigenic peptides must be presented by the HLA-II molecules HLA-DR, HLA-DQ, or HLA-DP. While antigen-presenting cells (APCs) constitutively express HLA-II, various other cell types start to express HLA-II when they are exposed to IFNγ (<xref ref-type="bibr" rid="bib14">Chang and Flavell, 1995</xref>; <xref ref-type="bibr" rid="bib81">Siegrist et al., 1995</xref>; <xref ref-type="bibr" rid="bib84">Steimle et al., 1993</xref>; <xref ref-type="bibr" rid="bib89">Ting and Trowsdale, 2002</xref>). Activated CD4 + T cells efficiently produce IFNγ, leading to a positive feed-forward loop of increased HLA-II presentation and enhanced CD4 + T cell recognition in the infected niche. Constitutive as well as IFNγ-induced HLA-II expression are both mediated by the class II transactivator (CIITA), which is the essential and sufficient master regulator of the transcription of the genes in the HLA-II locus. Accordingly, CIITA and its co-factors control the expression of the classical HLA-II molecules DR, DQ, DP, the non-classical HLA-II peptidome editors DM and DO, and the invariant chain (Ii, also known as CD74) (<xref ref-type="bibr" rid="bib10">Boss and Jensen, 2003</xref>; <xref ref-type="bibr" rid="bib89">Ting and Trowsdale, 2002</xref>). The absence of functional CIITA results in a loss of HLA-II presentation, leading to a hereditary immunodeficiency called type II bare lymphocyte syndrome (BLS) that causes an extreme vulnerability to infections. In accordance with the relevance of CD4 + T cells and CIITA-driven HLA-II presentation, BLS patients frequently suffer from severe, persistent HCMV infections (<xref ref-type="bibr" rid="bib23">Elhasid and Etzioni, 1996</xref>; <xref ref-type="bibr" rid="bib46">Klein et al., 1993</xref>).</p><p>For allogenic hematopoietic cell therapy (HCT), the HLA-DP locus is of particular interest given the frequent incompatibility of patients and donors (<xref ref-type="bibr" rid="bib25">Fleischhauer and Shaw, 2017</xref>), the allotype dependency of peptide presentation and recognition by alloreactive CD4 + T cells (<xref ref-type="bibr" rid="bib2">Arrieta-Bolaños et al., 2022</xref>; <xref ref-type="bibr" rid="bib67">Meurer et al., 2021</xref>; <xref ref-type="bibr" rid="bib102">Yamashita et al., 2017</xref>), and the relevance for chronic virus infections as indicated by the strong association of HLA-DPB1 SNPs with chronic hepatitis B virus (HBV) infections (see e.g. <xref ref-type="bibr" rid="bib43">Kamatani et al., 2009</xref>). CD4 + T cells recognizing HLA-DP-restricted peptides have also been described for HCMV (<xref ref-type="bibr" rid="bib1">Ameres et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Hyun et al., 2020</xref>; <xref ref-type="bibr" rid="bib47">Klobuch et al., 2022</xref>; <xref ref-type="bibr" rid="bib85">Stevanovic et al., 2013</xref>; <xref ref-type="bibr" rid="bib96">Ventura et al., 2012</xref>), but to our knowledge, an HCMV-encoded protein antagonizing HLA-DP-restricted antigen presentation has not yet been described.</p><p>HCMV-propagating cells such as human fibroblasts, endothelial cells, and epithelial cells are capable of inducing HLA-II presentation after exposure to IFNγ. Moreover, cells serving as a reservoir for HCMV latency, e.g., monocytes, constitutively express HLA-II. CD4 + T cells can recognize HCMV-derived antigens known to be expressed during latency, leading to the recognition of latently infected cells and the production of IFNγ and/or cytotoxic responses (<xref ref-type="bibr" rid="bib61">Mason et al., 2013</xref>). These facts raise the question of how HCMV circumvents CD4 + T cell-mediated elimination during productive replication as well as latency.</p><p>Here, we show that the HCMV-encoded G protein-coupled receptor (GPCR) pUS28 directly targets CIITA, impairing HLA-II presentation and CD4 + T cell recognition. Importantly, pUS28 is among the few viral proteins abundantly expressed during both productive replication as well as experimental and natural latency (<xref ref-type="bibr" rid="bib5">Beisser et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Cheung et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Goodrum et al., 2002</xref>; <xref ref-type="bibr" rid="bib50">Krishna et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Krishna et al., 2017a</xref>). Thus, our data reveal a novel mechanism employed by HCMV to circumvent the recognition by CD4 + T cells during different stages of infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>HCMV counteracts IFNγ-induced HLA-DP induction</title><p>Given the aforementioned relevance of HLA-DP in HCT and chronic virus infections, we interrogated if and how HCMV affects HLA-DP induction and presentation. IFNγ induced the upregulation of HLA-DP on the surface of HCMV-permissive fibroblasts (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>), whereas this was not the case after treatment with IFNα or TNFα (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Longer periods of IFNγ incubation led to an increase of HLA-DP and HLA-DR on the cell surface (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Despite the fact that the IFNγ-induced induction of HLA-DR and HLA-DP were clearly evident, professional antigen-presenting cells such as monocyte-derived dendritic cells still reached higher HLA-II surface levels (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In clear contrast to uninfected fibroblasts, the upregulation of HLA-DP by IFNγ was prevented in HCMV-infected cells (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). Interestingly, the same inhibitory phenotype was observed upon infection with HCMV mutants lacking the <italic>US2-6</italic> or the <italic>US2-11</italic> gene region (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>), that comprise the genes for pUS2 and pUS3, which degrade HLA-DRα and HLA-DMα (<xref ref-type="bibr" rid="bib91">Tomazin et al., 1999</xref>) and block the assembly of HLA-DRα/β heterodimers (<xref ref-type="bibr" rid="bib35">Hegde et al., 2002</xref>), respectively. These data indicate that HCMV encodes so far unknown antagonists of IFNγ-induced HLA-DP presentation located outside of the <italic>US2-11</italic> gene region.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>IFNγ-induced human leukocyte antigen (HLA)-DP expression is abrogated in Human cytomegalovirus (HCMV)-infected fibroblasts<bold>.</bold></title><p>(<bold>A</bold>) MRC-5 fibroblasts were either left untreated or were treated with 200 U/ml IFNγ. At 72 hr post-treatment, cells were stained with anti-HLA-DP antibody and analyzed by flow cytometry. w/o, untreated. (<bold>B</bold>) MRC-5 fibroblasts were either left untreated or were treated with 200 U/ml IFNγ, 200 U/ml IFNα, or 20 ng/ml TNFα. At 48 hr post-treatment, cells were stained with anti-HLA-DP antibody and analyzed by flow cytometry. w/o, untreated. (<bold>C</bold>) MRC-5 fibroblasts were either left untreated or were treated with 200 U/ml IFNγ for 1, 2, or 3 d. Cells were stained with anti-HLA-DP or anti-HLA-DR antibodies and analyzed by flow cytometry. (<bold>D</bold>) MRC-5 fibroblasts were either mock infected or were infected (MOI 3) with AD169 (HCMV), AD169-BAC2 (HCMVΔUS2-6), or AD169-BAC2ΔUS2-11 (HCMVΔUS2-11). At 4 hr post-infection, cells were treated with 200 U/ml IFNγ. After 48 hr of treatment, cells were stained with anti-HLA-DP antibody and analyzed by flow cytometry. w/o, untreated. (<bold>E</bold>) The mean fluorescence intensity (MFI) values of HLA-DP expression of untreated or IFNγ-treated MRC-5 cells, mock-treated or infected (as in <bold>D</bold>) (n=4). Significance was calculated by two-way ANOVA test. Comparisons are shown when statistically significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Human leukocyte antigen (HLA)-DP expression of dendritic cells.</title><p>(<bold>A</bold>) Dendritic cells were obtained from maturation of monocytes. Cells were stained with anti-HLA-DP or HLA-DR antibodies and analyzed by flow cytometry.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>The HCMV-encoded pUS28 antagonizes CIITA-induced HLA-II expression</title><p>Since HCMV prevented HLA-DP induction, we aimed to identify the responsible gene product(s). To this end, we applied an expression library, which has been previously described (<xref ref-type="bibr" rid="bib75">Salsman et al., 2008</xref>), comprising more than 150 canonical HCMV genes, to screen for HLA-DP antagonists. To minimize potentially confounding effects of viral antagonists of IFN signaling acting upstream of CIITA induction, we set up the screen by co-transfecting a CIITA expression plasmid together with individual vectors encoding HCMV proteins. Afterwards, the CIITA-induced HLA-DP cell surface expression was quantified by flow cytometry (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The screen provided candidates for the observed antagonism of HLA-DP induction, including pUS9, pUS19, pp65-UL83, and pUS28. For pp65-UL83, <xref ref-type="bibr" rid="bib70">Odeberg et al., 2003</xref> have described a lysosomal sequestration and subsequent degradation of HLA-DR (<xref ref-type="bibr" rid="bib70">Odeberg et al., 2003</xref>), and pUS9 targets several host proteins including HLA/MHC-like molecules such as MR1 and MICA∗008 (<xref ref-type="bibr" rid="bib79">Seidel et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Ashley et al., 2023</xref>). Due to its relevance for the HCMV biology, we further assessed the influence of pUS28 on the CIITA-dependent induction of genes in the HLA-II locus. Validation experiments substantiated that pUS28 was reproducibly capable of significantly diminishing CIITA-induced HLA-DP surface expression (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and data not shown). Similar to its effect on HLA-DP, pUS28 also significantly diminished the cell surface expression of the presenting molecules HLA-DR (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>) and HLA-DQ (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) as well as the peptide editor HLA-DM (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Given that different cell types express varying levels of CIITA, we tested the dose-response relationship between CIITA and pUS28. While increasing amounts of CIITA dose-dependently drove HLA-DP and HLA-DR expression in transfected cells, pUS28 significantly and dose-dependently inhibited surface levels of HLA-DR (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) and HLA-DP (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), at different levels of CIITA abundance.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Human cytomegalovirus (HCMV)-pUS28 functions as an antagonist of the class II transactivator (CIITA)-induced human leukocyte antigen (HLA) class II upregulation.</title><p>(<bold>A</bold>) HeLa cells were co-transfected with a CIITA expression construct and a library of single HCMV gene-encoding plasmids or empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DP antibody and analyzed by flow cytometry. Cell surface expression of HLA-DP was normalized to cells transfected with CIITA expression construct and empty vector. The percentage of HLA-DP-positive cells is shown. (<bold>B/C</bold>) HeLa cells were co-transfected with a CIITA expression construct and indicated plasmids or empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DP (<bold>B</bold>) or anti-HLA-DR (<bold>C</bold>) antibody and analyzed by flow cytometry. Cell surface expression of HLA class II was normalized to cells transfected with CIITA expression construct and empty vector. The percentage of HLA-DP- or HLA-DR-positive cells is shown (mean values ± SD, n=4–8). Significance was calculated by the Kruskal-Wallis test compared to empty vector control. Comparisons are shown when statistically significant. Untrans, untransfected. Vector, empty vector control. (<bold>D</bold>) HeLa cells were either left untreated or were co-transfected with a CIITA expression construct and pcDNA:US28-HA or empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DP, anti-HLA-DR, or anti-HLA-DQ antibody or intracytoplasmic stained with anti-HLA-DM antibody and analyzed by flow cytometry. (<bold>E/F</bold>) HeLa cells were co-transfected with indicated amounts of CIITA expression construct and increasing doses of pcDNA:US28-HA, a control plasmid (pcDNA:US29-HA), or empty vector. The total DNA amount of each transfection was adjusted to the same level by adding the respective amount of empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DR (<bold>E</bold>) and anti-HLA-DP (<bold>F</bold>) antibodies and analyzed by flow cytometry. The percentage of HLA-DR- and HLA-DP-positive cells is shown (n=5–8). Significance was calculated by two-way ANOVA test. Comparisons are shown when statistically significant. Vector, empty vector control. Control, control plasmid.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig2-v1.tif"/></fig></sec><sec id="s2-3"><title>pUS28 downregulates CIITA post-transcriptionally</title><p>To probe into the underlying molecular mechanism of the pUS28-mediated HLA-II inhibition, untagged or epitope-tagged CIITA was co-expressed with pUS28 or a control protein. Afterwards, transcript levels of <italic>CIITA</italic> were quantified by semi-quantitative reverse transcriptase (RT)-PCR. Irrespective of the presence or absence of pUS28, the levels of tagged as well as untagged <italic>CIITA</italic> mRNA remained unaltered (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), while the amounts of HLA-DP and HLA-DR mRNA were decreased (data not shown). In contrast to the unchanged mRNA levels of <italic>CIITA</italic>, a parallel evaluation of CIITA protein amounts revealed a drastic reduction upon pUS28 co-expression (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), suggesting a post-transcriptional effect of pUS28 on CIITA. The CIITA down-modulating capacity of pUS28 was observed with different plasmid preparations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), and was specific for CIITA, since control proteins such as the enhanced yellow fluorescent protein (EYFP) remained unaffected (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), arguing against a general influence of pUS28 on transcription or translation. The effect on CIITA was also not an overarching capacity of viral chemokine receptor homologs, since the protein pUS27, a GPCR encoded by the neighboring gene in the viral genome, did not decrease CIITA protein amounts (<xref ref-type="fig" rid="fig3">Figure 3D</xref>) or HLA-DP surface levels (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>pUS28 downregulates class II transactivator (CIITA) post-transcriptionally.</title><p>(<bold>A/B</bold>) HeLa cells were either left untreated or were co-transfected with CIITA or CIITA-3xFLAG expression constructs and pcDNA:US28-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, cells were harvested and split for preparation of total RNA and protein lysate. RNA samples were used for semi-quantitative RT-PCR with indicated gene-specific primers (<bold>A</bold>) and protein lysates were analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags (<bold>B</bold>). (<bold>C</bold>) HeLa cells were either left untreated or were co-transfected with the indicated plasmids. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. #1, #2, different plasmid preparations. (<bold>D</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pcDNA:US27-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. (<bold>E</bold>) HeLa cells were co-transfected with CIITA expression construct and increasing doses of pcDNA:US28-HA or pcDNA:US27-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. The total DNA amount of each transfection was adjusted to the same level by adding the respective amount of empty vector. At 48 hr post-transfection, cells were stained with anti-human leukocyte antigen (HLA)-DP antibody and analyzed by flow cytometry. The percentage of HLA-DP-positive cells normalized to empty vector control is shown (n=3). The different transfection conditions were compared to the control condition (vector) by one-way ANOVA test. Comparisons are shown when statistically significant. Untrans, untransfected. Vector, empty vector control. Control, pIRESNeo-FLAG/HA-EYFP.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig3">Figure 3A-D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3A-D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig3-v1.tif"/></fig></sec><sec id="s2-4"><title>Global mass spectrometry confirmed the pUS28-mediated decrease of the CIITA abundance and identified downstream targets of the HLA class II pathway</title><p>To address the influence of pUS28 on CIITA and the proteome, we performed global mass spectrometry (MS) analyses in which we compared control cells with cells expressing either pUS28, CIITA, or both (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). As expected, our MS analyses confirmed the expression of pUS28 (<xref ref-type="fig" rid="fig4">Figure 4A-C</xref>). In agreement with previous data, pUS28 led to a significant upregulation of IL-6 (<xref ref-type="bibr" rid="bib82">Slinger et al., 2010</xref>), and attenuated AP-1 components (<xref ref-type="bibr" rid="bib51">Krishna et al., 2019</xref>) (here JunD) (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>), validating our experimental setup. These unbiased MS analyses confirmed the significant downregulation of CIITA by pUS28 (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Other components of the CIITA enhanceosome, such as RFX5, RFX-AP, NF-YA, and NF-YC, as well as recently described factors (<xref ref-type="bibr" rid="bib44">Kiritsy et al., 2021</xref>) that influence HLA-II transcription showed constitutive, CIITA-independent expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Conversely, CD74 - the invariant chain required for proper maturation and loading of HLA class II molecules - was significantly induced by CIITA, unless pUS28 was co-expressed (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). The negative effect of pUS28 on CIITA-driven CD74 expression was confirmed by flow cytometry (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). In contrast to several other CIITA-regulated genes, CD74 is not encoded by the HLA-II locus on chromosome 6. Thus, the fact that pUS28 prevents CIITA-induced CD74 induction suggests that pUS28 elicits the negative effect on CIITA target genes independent of their genomic localization in the MHC-II locus.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Global proteome analysis revealed that pUS28 targets class II transactivator (CIITA) and affects the CIITA-regulated protein CD74.</title><p>(<bold>A/B</bold>) HeLa cells were either left untreated or were transfected with CIITA-3xFLAG expression construct, pcDNA:US28-HA, or both. At 24 hr post-transfection, whole cell lysates were generated and subjected to mass spectrometric analysis of protein abundance. Volcano plots showing log2 (ratio of means) (x-axis) versus significance (y-axis) of the comparison of untreated and pUS28-expressing cells (<bold>A</bold>) or cells expressing CIITA in the presence or absence of pUS28 (<bold>B</bold>). Proteins are indicated as gray dots, highlighted in red are IL-6 (known to be upregulated by pUS28), co-factors of HLA-II transcription and signaling, CIITA, and pUS28. (<bold>C–G</bold>) Changes in the abundance of selected proteins detected by MS: (<bold>C</bold>) pUS28, (<bold>D</bold>) IL-6, (<bold>E</bold>) JunD, (<bold>F</bold>) CIITA, (<bold>G</bold>) CD74. Depicted are log2 (intensity) values of untreated cells, cells expressing either CIITA, pUS28, or both (n=4). Significance was calculated by one-way ANOVA test. Comparisons are shown when statistically significant. (<bold>H</bold>) HeLa cells were either left untreated or were co-transfected with a CIITA expression construct and pcDNA:US28-HA or empty vector. At 48 hr post-transfection, cells were stained with anti-CD74 antibody and analyzed by flow cytometry. Untrans, untransfected. Vector, empty vector control.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Global proteome analysis showed that the other components of the CIITA enhanceosome and recently described regulators of HLA-II transcription are constitutively expressed.</title><p>(<bold>A</bold>) Simplified schema of the CIITA enhanceosome. This panel was created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/7ijpgpr">BioRender.com</ext-link>. (<bold>B</bold>) Changes in the abundance of selected proteins measured by MS: RFX5, RFX-AP, NF-YA, NF-YC, GSK3A, GSK3B, MED16 as log2 (intensity) values of untreated cells or cells expressing CIITA (n=4). Significance was calculated by one-way ANOVA test. Comparisons are shown when statistically significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>The ability of pUS28 to decrease HLA class II expression is evolutionarily conserved and evident in loss-of-function as well as gain-of-function experiments</title><p>To validate the effect of pUS28 on CIITA in an independent model, we generated fibroblasts expressing the viral GPCRs pUS28 or pUS27 in a doxycycline-inducible manner. While doxycycline treatment in parental and pUS27-expressing fibroblasts had no significant effect on the IFNγ-induced HLA-DP expression, HLA-DP cell surface levels were significantly decreased upon pUS28 induction (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Additionally, an HCMV mutant lacking the gene <italic>US28</italic> (ΔUS28-HCMV) was generated and tested regarding its effect on HLA-II. Leukemic cells that constitutively express HLA-II were either infected with wild-type (wt) HCMV or ΔUS28-HCMV. In accordance with aforementioned data, wt HCMV significantly decreased the percentage of HLA-DP- and HLA-DR-positive cells in comparison to mock-treated cells. In contrast, ΔUS28-HCMV showed an impaired ability to downregulate HLA-II (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). We also assessed the effect of the mouse cytomegalovirus (MCMV)-encoded pUS28 homolog pM33 regarding its capacity to downregulate human (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) and mouse CIITA (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). We found that pM33 and pUS28 both downregulate human and mouse CIITA, suggesting an evolutionarily conserved function.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The ability of pUS28 to decrease human leukocyte antigen (HLA) class II expression is evolutionary conserved and evident in loss-of-function as well as gain-of-function experiments.</title><p>(<bold>A</bold>) HeLa TRex Flip-in:US28HA (US28) and HeLa TRex Flip-in:US27HA (US27) cells were either treated with 200 µg/ml doxycycline or left untreated. At 24 hr after treatment, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. Furthermore, HeLa TRex Flip-in (parental), HeLa TRex Flip-in:US28HA (US28), and HeLa TRex Flip-in:US27HA (US27) were either treated with 200 U/ml IFNγ or a combination of 200 µg/ml doxycycline and 200 U/ml IFNγ. After 48 hr of treatment, cells were stained with anti-HLA-DP antibody and analyzed by flow cytometry. The fold induction of the mean fluorescence intensity (MFI) values of HLA-DP expression of cells in presence compared to absence of doxycycline treatment (taking the change over background into account) are shown (n=5). Significance was calculated by one-way ANOVA test. Comparisons are shown when statistically significant. (<bold>B/C</bold>) UoC-B6 cells were either mock infected or were infected (MOI 3) with AD169-BAC2-UL131rep (wt) or AD169-BAC2-UL131repΔUS28 (ΔUS28). At 2 hr post-infection, medium change was performed. At 3 d post-infection, cells were stained with anti-HLA-DP and anti-HLA-DR antibodies and analyzed by flow cytometry. The percentage of HLA-DP- (<bold>B</bold>) and HLA-DR-positive (<bold>C</bold>) cells is shown (n=5). Significance was calculated by RM one-way ANOVA test. Comparisons are shown when statistically significant. (<bold>D</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pcDNA:M33-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector pcDNA3.1. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. #1, #2, different plasmid preparations. (<bold>E</bold>) HeLa cells were either left untreated or were co-transfected with 3xFLAG-mouseCIITA expression construct and pcDNA:US28-HA, pcDNA:M33-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, protein lysates were prepared and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig5">Figure 5A, D and E</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig5">Figure 5A, D and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>pUS28 interacts with CIITA and reduces its half-life irrespective of the G protein-coupling capacity</title><p>Next, we tested if pUS28 and CIITA physically interact. To circumvent the issue that CIITA levels were diminished to almost undetectable levels upon pUS28 co-expression, lysates either containing pUS28 or CIITA were combined before an immunoprecipitation (IP) was performed. The IP of pUS28 co-purified CIITA (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, upper panel) and vice versa (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, lower panel), indicating that both proteins form physical complexes. To test if pUS28 forces CIITA into a detergent-insoluble fraction, cell lysates were prepared with a denaturing lysis buffer (based on high urea concentrations) and subjected to immunoblot analysis. This approach did not lead to the reappearance of CIITA (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Irrespective of the absence or presence of pUS28, we could not detect CIITA in cell culture supernatants (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>), arguing against pUS28-mediated CIITA shedding. Since we did not find evidence for sequestration or shedding, we tested for a pUS28-mediated CIITA degradation. To this end, we compared the half-life of CIITA in the presence or absence of pUS28. Despite the inherently short half-life of CIITA (<xref ref-type="bibr" rid="bib77">Schnappauf et al., 2003</xref>), we observed a more rapid CIITA decay when pUS28 was co-expressed (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>pUS28 physically interacts with class II transactivator (CIITA) and reduces its half-life.</title><p>(<bold>A</bold>) HeLa cells were either left untreated or were transfected with CIITA-3xFLAG expression construct or pcDNA:US28-HA. At 24 hr post-transfection, protein lysates were generated and an IP with HA- or FLAG-specific mouse monoclonal antibodies was performed either with unmodified samples or with mixed samples of CIITA- and US28-transfected cells. The lysates and IP samples were analyzed by immunoblot to test CIITA and pUS28 co-precipitation. (<bold>B</bold>) HeLa cells were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA or empty vector. At 16 hr post-transfection, cells either were left untreated or were incubated with 50 µg/ml cycloheximide (CHX) for indicated periods. Protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. All samples were run on one gel and detected on the same membrane (<xref ref-type="fig" rid="fig5">Figure 5</xref>). For better comparison, US28 samples were presented underneath the empty vector samples.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig6">Figure 6A-B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6">Figure 6A-B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>pUS28 diminishes class II transactivator (CIITA) protein levels also in denaturing lysis buffer.</title><p>HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, protein lysates were prepared in RIPA (<bold>A</bold>) or denaturing lysis buffer based on 5 M urea (<bold>B</bold>) and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, indicating the relevant bands and treatment.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>The loss of class II transactivator (CIITA) in pUS28-expressing cells is not caused by CIITA shedding as indicated by its absence in cell supernatants.</title><p>HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, empty vector, or pIRESNeo-FLAG/HA-EYFP (control). At 24 hr post-transfection, protein lysates from transfected cells were prepared and proteins from the supernatant derived from aforementioned cells were precipitated. Protein amounts were analyzed by immunoblot using antibodies recognizing the indicated proteins or the respective epitope tags.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s2sdata2"><label>Figure 6—figure supplement 2—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>pUS28 reduces the half-life of class II transactivator (CIITA).</title><p>Related to <xref ref-type="fig" rid="fig6">Figure 6B</xref>, uncropped gel. HeLa cells were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA or empty vector. At 16 hr post-transfection, cells either were left untreated or were incubated with 50 µg/ml cycloheximide (CHX) for indicated periods. Protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig6-figsupp3-v1.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>Inhibition of the usual protein degradation pathways does not restore class II transactivator (CIITA) protein levels in the presence of pUS28.</title><p>(<bold>A/B</bold>) Cells were either left untransfected or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA or empty vector. At 16 hr post-transfection, cells were either left untreated (w/o) or were treated with MG-132 (10 µM), MLN4924 (2.5 µM), TAS4464 (1 µM), Bortezomib (1 µM), 3-methyladenine (10 mM, 3-MA), Bafilomycin (1 µM, BA), Chloroquine (50 µM, CQ), ammonium chloride (5 mM, NH<sub>4</sub>Cl), Z-VAD-FMK (50 µM, ZVAD), Pepstatin A (10 µM, PepA), E-64 (5 µM), PMSF (1 mM), pan-protease inhibitor cocktail (1:200, PIC), Dynasore (100 µM, Dyno), or Decanoyl-RVKR-CMK (10 µM, CMK). At 6 hr post-treatment start, protein lysates were prepared and analyzed by immunoblot. Untrans, untransfected. Vector, empty vector control.</p><p><supplementary-material id="fig6s4sdata1"><label>Figure 6—figure supplement 4—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig6s4sdata2"><label>Figure 6—figure supplement 4—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig6-figsupp4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig6-figsupp4-v1.tif"/></fig></fig-group><p>Intriguingly, a panel of inhibitors targeting different cellular degradation pathways (e.g. the inhibitors of the ubiquitin-proteasome pathway MG-132 and Bortezomib, the inhibitors of UBA3-dependent neddylation blocking cullin-RING ubiquitin ligase activity MLN4924 and TAS4464, the autophagy inhibitors bafilomycin and 3-MA, the inhibitors of lysosomal acidification chloroquine and ammonium chloride, the pan-caspase inhibitor Z-VAD-FMK, the protease inhibitors Pepstatin A, E-64, PMSF, and a pan-protease inhibitor cocktail, as well as the dynamin inhibitor Dynasore and the convertase inhibitor Decanoyl-RVKR-CMK) all failed to significantly and reproducibly restore CIITA levels in pUS28-expressing cells (<xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4</xref> and data not shown), implying that pUS28 reduces CIITA levels either by redundant or unusual degradation processes.</p><p>To assess if the G-protein signaling of pUS28 is essential for the downregulation of CIITA, we compared wt-pUS28 and R129A-pUS28. The latter is a well-studied mutant of pUS28 that harbors a single amino acid substitution at position 129 (arginine to alanine) within the canonical DRY motif, abrogating G-protein signaling without compromising the subcellular localization or internalization (<xref ref-type="bibr" rid="bib99">Waldhoer et al., 2003</xref>; visualized in <xref ref-type="fig" rid="fig7">Figure 7A</xref>). Both pUS28 variants diminished CIITA protein levels (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Conversely, the intracellular C terminus turned out to be indispensable for the CIITA degradation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). In accordance with these findings, R129A-pUS28 and wt-pUS28 similarly diminished the surface expression of HLA-DP (<xref ref-type="fig" rid="fig7">Figure 7D</xref>) and HLA-DR (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), while the mutant lacking the C terminus (US28-ΔC) did not (<xref ref-type="fig" rid="fig7">Figure 7F and G</xref>), indicating that pUS28 targets CIITA through its C terminus. In IP experiments, pUS28-ΔC co-purified CIITA (<xref ref-type="fig" rid="fig7">Figure 7H</xref>), suggesting that the lack of the C terminus of pUS28 did not impair the physical interaction with CIITA but rather affected the degradation machinery. Further investigations of the C-terminal part of pUS28 revealed that amino acids in proximity to the transmembrane domain 7 were required for downregulation of CIITA as only a mutant lacking the whole C terminus completely lost the capability to target CIITA (<xref ref-type="fig" rid="fig7">Figure 7I</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>pUS28 targeting class II transactivator (CIITA) is independent of the G-protein coupling capacity but requires the C terminus of pUS28.</title><p>(<bold>A</bold>) Schematic overview of the structure of pUS28. All structural parts of the protein and the DRY motif are indicated. Mutation of the arginine in this motif to alanine (R129A) ablates G-protein coupling. This panel was created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/hfo3bbm">BioRender.com</ext-link>. (<bold>B</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pcDNA:US28-R129A-HA, pIRESNeo-FLAG/HA-EYFP, or empty vector. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. (<bold>C</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pcDNA:US28-ΔC-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. (<bold>D/E</bold>) HeLa cells were either left untreated or were co-transfected with CIITA expression construct and pcDNA:US28-HA, pcDNA:US28-R129A-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DP (<bold>D</bold>) or anti-HLA-DR (<bold>E</bold>) antibodies and analyzed by flow cytometry. Cell surface expression of HLA-DP or HLA-DR was normalized to cells co-transfected with CIITA expression construct and empty vector. The percentage of HLA-DP- and HLA-DR-positive cells is shown (n=3). The different transfection conditions were compared to the control condition (vector) by one-way ANOVA test. Additionally, US28-R129A-HA was compared to US28-HA. Comparisons are shown when statistically significant. (<bold>F/G</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pcDNA:US28-HA, pcDNA:US28-ΔC-HA, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 48 hr post-transfection, cells were stained with anti-HLA-DP (<bold>F</bold>) or anti-HLA-DR (<bold>G</bold>) antibodies and analyzed by flow cytometry. Cell surface expression of HLA-DP or HLA-DR was normalized to cells transfected with CIITA expression construct and empty vector. The percentage of HLA-DP- and HLA-DR-positive cells is shown (n=3). The different transfection conditions were compared to the control condition (vector) by one-way ANOVA test. Additionally, US28-ΔC-HA was compared to US28-HA. Comparisons are shown when statistically significant. (<bold>H</bold>) HeLa cells were either left untreated or were transfected with CIITA-3xFLAG expression construct or pcDNA:US28-ΔC-HA. At 24 hr post-transfection, protein lysates were generated and an IP with HA-specific mouse monoclonal antibody was performed either with unmodified samples or with mixed samples of CIITA- and US28-transfected cells. The lysates and IP samples were analyzed by immunoblot to test CIITA and pUS28-ΔC co-precipitation. (<bold>I</bold>) HeLa cells were either left untreated or were co-transfected with CIITA-3xFLAG expression construct and pIRES:US28-HA, different pIRES:US28-ΔC-HA mutants, pIRESNeo-FLAG/HA-EYFP (control) or empty vector. At 24 hr post-transfection, protein lysates were generated and analyzed by immunoblot using antibodies detecting the indicated proteins or the respective epitope tags. Untrans, untransfected. Vector, empty vector control. ΔC (1-297), C-terminal (aa 298–354) deletion mutant of pUS28. 1–313, C-terminal (aa 314–354) deletion mutant of pUS28. 1–329, C-terminal (aa 330–354) deletion mutant of pUS28. 1–345, C-terminal (aa 346–354) deletion mutant of pUS28. R129A, point mutation mutant of pUS28. Control, pIRESNeo-FLAG/HA-EYFP.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>PDF files containing original western blots for <xref ref-type="fig" rid="fig7">Figure 7A-B and H-I</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig7-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7sdata2"><label>Figure 7—source data 2.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig7">Figure 7A-B and H-I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-96414-fig7-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig7-v1.tif"/></fig></sec><sec id="s2-7"><title>pUS28 antagonizes HCMV-specific CD4+ T cells</title><p>After identifying pUS28 as a viral antagonist of the CIITA-driven HLA class II expression and considering that pUS28 is expressed during HCMV latency, we aimed to investigate the relevance of pUS28 for immune recognition. HCMV-specific CD4 + T cells were enriched by antigen-dependent expansion using peripheral blood mononuclear cells (PBMCs) from HCMV-seropositive healthy individuals exposed to lysates derived from HCMV-infected fibroblasts (see schematic overview in <xref ref-type="fig" rid="fig8">Figure 8A</xref>). During the 24 hr re-stimulation phase, the HCMV-specific CD4 + T cells were co-cultured with HCMV antigen-loaded fibroblasts expressing CIITA together with pUS28, with pUS28-R129A or with an irrelevant protein. CD4 + T cell activation was evaluated by CD137 upregulation. HCMV-specific CD4 + T cells from HCMV-positive individuals vigorously responded to CIITA-expressing cells, but not to control cells that did not express CIITA (<xref ref-type="fig" rid="fig8">Figure 8B</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>), indicating a specific HLA-II-dependent T cell activation. In the presence of pUS28 or the mutant R129A-pUS28, the immune recognition of CIITA-expressing, antigen-loaded cells by HCMV-specific CD4 + T cells was significantly reduced (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Since CD4 + T cells are well-known for the ability to produce antiviral cytokines such as IFNγ, we assessed the cell culture supernatants collected after the 24 hr re-stimulation phase regarding their antiviral activity against HCMV. We conditioned human fibroblasts with the supernatants prior to the infection with an EGFP-expressing reporter HCMV. Afterwards, we quantified HCMV-induced EGFP expression (<xref ref-type="fig" rid="fig8">Figure 8C</xref>) and visualized the degree of HCMV infection by microscopy (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Supernatants from HCMV-specific CD4 + T cells stimulated with CIITA-expressing cells strongly inhibited HCMV-induced EGFP expression, while supernatants derived from CD4 + T cells stimulated in the presence of pUS28 showed diminished antiviral activity (<xref ref-type="fig" rid="fig8">Figure 8C and D</xref>). These data demonstrate that pUS28 inhibits the CIITA-driven and HLA-II-dependent CD4 + T cell activation in terms of the production of antiviral cytokines.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Activation of Human cytomegalovirus (HCMV)-specific CD4 + T cells is inhibited by pUS28.</title><p>(<bold>A</bold>) Schematic overview of the experimental setup. Peripheral blood mononuclear cells (PBMCs) of Human cytomegalovirus (HCMV)-seropositive healthy donors were isolated, pulsed with HCMV lysate, and incubated for 14 d, with an antigen refreshment step at day 7. Afterwards, cells were co-cultured with HeLa cells that were either left untreated or were co-transfected with class II transactivator (CIITA) expression construct and pcDNA:US28-HA, pcDNA:US28-R129A-HA, pIRESNeo-FLAG/HA-EYFP, or empty vector, 48 hr prior to co-culture, and were re-stimulated with mock or HCMV lysate. HeLa cells only expressing CD80 and the invariant chain (HeLa CD80/Ii) served as further negative control. After 24 hr of incubation, the specific T cell response was quantified by flow cytometry as percentage of gated CD4 + T cells expressing the activation marker CD137. This panel was created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/f2lvatc">BioRender.com</ext-link>. (<bold>B</bold>) Activation of HCMV-specific CD4 + T cells was measured as described in (<bold>A</bold>). Proportion of CD137-positive T cells was normalized to T cells activated by HeLa cells transfected with CIITA expression construct and empty vector, and pulsed with HCMV lysate. Mean values ± SD are depicted (n=4–10 different donors). Significance was calculated by one-way ANOVA test. Comparisons are shown when statistically significant. (<bold>C</bold>) MRC-5 cells were incubated with supernatants from HCMV-specific CD4 + T cells (<bold>B</bold>) or recombinant IFNγ in serial dilutions for 24 hr. Next, cells were infected with BAC20-EGFP at an MOI of 0.05 and HCMV-induced EGFP expression was measured at 5 d post-infection (n=2). (<bold>D</bold>) MRC-5 cells were incubated and infected as in (<bold>C</bold>) and infected cells were visualized by fluorescence microscopy after 4 d of infection (square pictures) or whole-well imaging at 6 d post-infection (circle pictures). Untrans, untransfected. Vector, empty vector control. R129A, point mutation mutant of pUS28. Control, pIRESNeo-FLAG/HA-EYFP. Mock, uninfected. CMV Ag, HCMV lysate-treated. No Ag, mock lysate-treated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Activation of Human cytomegalovirus (HCMV)-specific CD4 + T cells is inhibited by pUS28.</title><p>Activation of HCMV-specific CD4+ T cells was detected by T cell activation assay. Proportion of CD4/CD137-positive T cells are depicted (n=10). Each line corresponds to one donor. Untrans, untransfected. Vector, empty vector control. Control, pIRESNeo-FLAG/HA-EYFP.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig8-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we identified pUS28 as HCMV-encoded antagonist of CIITA and CIITA-driven HLA class II expression (<xref ref-type="fig" rid="fig9">Figure 9</xref>). The viral protein was found to physically interact with CIITA, causing a post-transcriptional decline of the CIITA protein by an increased protein decay. This CIITA degradation was sufficient to decrease HLA-DR, HLA-DQ, HLA-DM, CD74/invariant chain, and HLA-DP expression and to abrogate activation of HCMV-specific CD4 + T cells. Despite its role as a highly relevant human pathogen, attenuated HCMVs became the basis for the development of promising vaccine vectors (e.g. for the vaccination against lentiviruses <xref ref-type="bibr" rid="bib71">Picker et al., 2023</xref>), which may benefit from the deletion of immune evasins such as US28, either in terms of enhanced immunogenicity and/or increased safety.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Model of the pUS28-mediated antagonism of class II transactivator (CIITA)-driven human leukocyte antigen (HLA)-II presentation and CD4 + T cell recognition.</title><p>The findings shown in this publication are consistent with the following model: pUS28 acts as Human cytomegalovirus (HCMV)-encoded antagonist of CIITA and CIITA-driven HLA class II expression. The pUS28-dependent CIITA degradation is sufficient to decrease antigen presentation by HLA-II molecules including HLA-DR and HLA-DP, and to reduce the activation of HCMV-specific CD4 + T cells. The CIITA antagonism is evolutionarily conserved in the mouse cytomegalovirus (MCMV)-encoded pM33. This figure was created using <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/nc0faun">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-fig9-v1.tif"/></fig><p>Briefly after its discovery as HCMV-encoded GPCR (<xref ref-type="bibr" rid="bib15">Chee et al., 1990</xref>), the striking homology of pUS28 to human CX3CR1 was noticed (<xref ref-type="bibr" rid="bib29">Gao et al., 1993</xref>) and its functionality as calcium-mobilizing beta chemokine receptor was documented (<xref ref-type="bibr" rid="bib30">Gao and Murphy, 1994</xref>). Since then, pUS28 has became one of the best-studied HCMV proteins, and several important immunological and viral functions have been assigned to this molecule. For example, it can act as a co-factor for the HIV entry (<xref ref-type="bibr" rid="bib72">Pleskoff et al., 1997</xref>), it mediates G protein-coupled intracellular signaling (<xref ref-type="bibr" rid="bib7">Billstrom et al., 1998</xref>), it sequesters RANTES/MCP-1 (<xref ref-type="bibr" rid="bib8">Bodaghi et al., 1998</xref>) and serves as fractalkine receptor (<xref ref-type="bibr" rid="bib12">Burg et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Kledal et al., 1998</xref>), it mediates vascular smooth muscle cell migration (<xref ref-type="bibr" rid="bib12">Burg et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Kledal et al., 1998</xref>; <xref ref-type="bibr" rid="bib65">Melnychuk et al., 2004</xref>; <xref ref-type="bibr" rid="bib86">Streblow et al., 1999</xref>; <xref ref-type="bibr" rid="bib87">Streblow et al., 2003</xref>), and it may act as an oncogene or onco-modulatory protein (<xref ref-type="bibr" rid="bib9">Bongers et al., 2010</xref>; <xref ref-type="bibr" rid="bib62">Maussang et al., 2006</xref>; <xref ref-type="bibr" rid="bib82">Slinger et al., 2010</xref>). In terms of its expression profile, pUS28 is special due to its presence in experimental and natural latency (<xref ref-type="bibr" rid="bib5">Beisser et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Cheung et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Goodrum et al., 2002</xref>; <xref ref-type="bibr" rid="bib50">Krishna et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Krishna et al., 2017a</xref>), constituting a drug target for the latent HCMV reservoir using specifically designed toxins (<xref ref-type="bibr" rid="bib49">Krishna et al., 2017b</xref>). Our study adds the inhibition of CIITA-induced HLA-II antigen presentation to the list of important pUS28 functions. The relevance of pUS28 for latency establishment and reactivation has been studied in huNSG mice (<xref ref-type="bibr" rid="bib18">Crawford et al., 2019</xref>). These mice develop certain aspects of a human T cell compartment (<xref ref-type="bibr" rid="bib56">Legrand et al., 2006</xref>), which may lead to HLA-II-restricted elimination of infected cells by CD4 + T cells. In addition to its influence on latency and reactivation, the herein documented ability of pUS28 to counteract CIITA-driven HLA-II presentation may influence the outcome of such experiments by effects of pUS28 on the CD4 + T cell recognition by the immune system. Similarly, pUS28-expressing mouse cytomegalovirus (MCMV) mutants have been studied in mice (<xref ref-type="bibr" rid="bib24">Farrell et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Legrand et al., 2006</xref>). In this regard, it may be relevant to highlight that the HCMV-encoded pUS28 and its MCMV homolog pM33 are both capable of downregulating mouse CIITA (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>Elegant work by the Sinclair laboratory revealed that pUS28, besides its function as GPCR and latency regulator, targets certain host proteins such as MNDA/PYHIN3 and IFI16/PYHIN2 for rapid degradation. In contrast to the effect on CIITA shown here, however, this degradation was dependent on GPCR signaling as indicated by the restoration of target protein levels when R129 was mutated (<xref ref-type="bibr" rid="bib22">Elder et al., 2019</xref>). Although CIITA and HLA-DP levels were neither assessed nor discussed, the same work documented a negative effect of pUS28 on constitutive HLA-DR expression, while no difference between wt-pUS28 and an R129A mutant with regard to the IFNγ-induced HLA-DR expression was observed (<xref ref-type="bibr" rid="bib22">Elder et al., 2019</xref>). Importantly, <xref ref-type="bibr" rid="bib22">Elder et al., 2019</xref> and <xref ref-type="bibr" rid="bib83">Slobedman et al., 2002</xref> showed that latently infected primary human CD14 + monocytes and human fetal liver hematopoietic cells exhibit less HLA-DR on the surface compared to uninfected cells (<xref ref-type="bibr" rid="bib22">Elder et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Slobedman et al., 2002</xref>). Our data regarding the targeting of CIITA by pUS28 now provide a parsimonious molecular explanation for these findings, and extend it to other highly relevant HLA-II molecules including CD74, HLA-DM, HLA-DQ, and HLA-DR – which is very well in line with findings by <xref ref-type="bibr" rid="bib80">Shnayder et al., 2020</xref> who showed an inverse correlation between HCMV transcripts and CD74 as well as HLA-II expression in CD14 + monocytes (<xref ref-type="bibr" rid="bib80">Shnayder et al., 2020</xref>).</p><p>Recent work with the MCMV model showed that the deletion of the <italic>US28</italic> homolog <italic>M33</italic> results in altered MHC-I presentation in an allotype-specific manner (H-2L<sup>d</sup> and H-2K<sup>d</sup> being downregulated in an <italic>M33</italic>-dependent manner, but not H-2D<sup>d</sup>) (<xref ref-type="bibr" rid="bib101">White et al., 2022</xref>). Our data show that pM33 targets mouse CIITA (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), raising the intriguing question if pM33 also affects the MHC-II-dependent recognition of MCMV-infected cells by CD4 + T cells. Furthermore, it will be interesting to study if and how pM33 cooperates with the other MCMV-encoded GPCR pM78, which is necessary but not sufficient for a post-transcriptional attack on MHC-II molecules in the endosome (<xref ref-type="bibr" rid="bib103">Yunis et al., 2018</xref>).</p><p>Previous studies focused on the interplay between HCMV infection and HLA-DR presentation, largely neglecting other HLA-II molecules such as HLA-DP. Work by <xref ref-type="bibr" rid="bib68">Miller et al., 1998</xref> showed that HCMV counteracts IFNγ-induced gene expression, partly by inducing the proteasomal degradation of JAK1, leading to diminished CIITA and HLA-DRα induction when HCMV-infected cells are exposed to IFNγ (<xref ref-type="bibr" rid="bib68">Miller et al., 1998</xref>). Furthermore, HCMV targets constitutive as well as induced CIITA-dependent HLA-II expression at multiple levels by a multipronged attack, comprising the inhibition of (I) IFN-JAK-STAT signaling (<xref ref-type="bibr" rid="bib53">Le et al., 2008</xref>; <xref ref-type="bibr" rid="bib59">Le Trilling et al., 2020</xref>; <xref ref-type="bibr" rid="bib68">Miller et al., 1998</xref>), (II) constitutive CIITA transcription (<xref ref-type="bibr" rid="bib55">Lee et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Sandhu and Buchkovich, 2020</xref>), (III) CIITA protein stability (as shown here), and (IV) HLA-DR degradation and translocation (<xref ref-type="bibr" rid="bib36">Hegde and Johnson, 2003</xref>; <xref ref-type="bibr" rid="bib35">Hegde et al., 2002</xref>; <xref ref-type="bibr" rid="bib91">Tomazin et al., 1999</xref>). This high level of redundancy may also explain why others concluded, based on loss-of-function experiments, that the <italic>US</italic> gene region comprising <italic>US28</italic> is dispensable for the inhibition of HLA-DR presentation (<xref ref-type="bibr" rid="bib76">Sandhu and Buchkovich, 2020</xref>), while we observed a clear gain-of-function regarding HLA-II inhibition upon pUS28 expression and an impaired, but not completely abrogated, ability to decrease HLA class II expression by ΔUS28-HCMV.</p><p>HLA-II-restricted CD4 + T cell immunity to HCMV is crucial for the control of the lifelong infection by this virus. Its impairment in immunocompromised patients, including HCT recipients, is associated with considerable clinical risks. The present study is the first to identify a mechanism by which HCMV downregulates HLA-DP. HCMV accomplishes the CIITA degradation by pUS28 which occurs even in the absence of other HCMV-encoded proteins. Based on the aforementioned role of pUS28 for HCMV latency, it is tempting to speculate that pUS28 may shield latently infected cells from HLA-II-restricted CD4 + T lymphocytes.</p><p>In our introduction, we referred to the wealth of knowledge regarding the critical importance of CD4 + T cells for the immune control of cytomegaloviruses in mouse and rhesus models as well as in humans. These findings seem to contradict the multitude of CMV-encoded inhibitors of constitutive and induced HLA-II presentation. How can these two, at first glance mutually exclusive, facts be reconciled? The first argument is that cytomegaloviruses and their hosts are situated in an evolutionary red-queen race that establishes a hard-fought equilibrium. Thus, the residual CD4 + T cell-mediated immune control recognizing CMV-infected cells presenting diminished HLA-II levels may still be crucial for host survival despite the existence of viral inhibitors. Another intriguing possibility is that a relevant fraction of the HLA-II-mediated CD4 + T cell activation might be elicited by cells that are resistant to HCMV infections, such as the recently described HLA-DR +NKG2C+memory NK cells (<xref ref-type="bibr" rid="bib17">Costa-García et al., 2019</xref>), which have been shown to be mediators of viral control in transplanted patients (<xref ref-type="bibr" rid="bib19">Davis et al., 2015</xref>). The elucidation of the complex molecular mechanisms governing HCMV immune evasion in the immunocompetent and the immunocompromised host will provide important guidance for the design of tailored protocols of risk protection, e.g., by vaccination, targeted cellular therapies or drugs that interfere with pUS28-mediated CIITA degradation.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Cells and cell lines</title><p>HeLa cells (ATCC CCL-2), HeLa CD80/Ii (<xref ref-type="bibr" rid="bib74">Rutten et al., 2010</xref>), HeLa TRex Flip-in cells (<xref ref-type="bibr" rid="bib13">Castello et al., 2012</xref>) and BJ-5ta cells (ATCC CRL-4001), ARPE-19 cells (ATCC CRL-2302), and MRC-5 fibroblasts (ATCC CCL-171) were grown in Dulbecco modified Eagle medium (DMEM, Gibco) supplemented with 10% (v/v) FCS (Sigma-Aldrich), 100 μg/ml streptomycin/100 U/ml penicillin (Gibco), and 2 mM glutamine (Gibco) at 37 °C in 5% CO<sub>2</sub>. Growth medium for BJ-5ta cells was further supplemented with hygromycin B (10 µg/ml, Invivogen), for HeLa TRex Flip-in cells with blasticidin (10 µg/ml, Invivogen) and normocin (100 µg/ml, Invivogen), and for HeLa TRex Flip-in:US28HA and HeLa TRex Flip-in:US27HA with geneticin (500 µg/ml, Invivogen), blasticidin (10 µg/ml, Invivogen), and normocin (100 µg/ml, Invivogen). UoC-B6 (CVCL_A304) cells were grown in RPMI 1640 medium (Gibco) supplemented with 10% (v/v) FCS (Sigma-Aldrich) and 100 μg/ml streptomycin/100 U/ml penicillin (Gibco) at 37 °C in 5% CO<sub>2</sub>. PBMCs were obtained from healthy blood donors from the University Hospital Essen after informed consent under Ethical Review Board approvals 14–5961-BO and 16–6769-BO, in accordance with the Declaration of Helsinki. HLA typing was performed by next generation sequencing as described (<xref ref-type="bibr" rid="bib52">Lange et al., 2014</xref>). All blood donors were HCMV seropositive and were selected according to their HLA-DPB1 and HLA-DRB1 typing matching the endogenously expressed HLA-DP and HLA-DR in HeLa cells.</p></sec><sec id="s4-2"><title>Generation of monocyte-derived dendritic cells</title><p>To obtain human dendritic cells, monocytes were isolated from PBMCs using a CD14 MicroBead kit (Miltenyi) according to the manufacturer’s instructions, and purity was validated by flow cytometry. For maturation of monocytes into dendritic cells, monocytes were first cultured for 3 d in RPMI 1640 (c.c.pro) supplemented with 10% (v/v) heat-inactivated human serum (Merck), 50 U/ml IL-2 (Miltenyi), 10 ng/ml IL-7, 5 ng/ml IL-15 (R&amp;D Systems), 10 ng/ml IL-4 (R&amp;D Systems) and 100 ng/ml GMCSF (Miltenyi). Immature dendritic cells were further differentiated into mature dendritic cells by culturing for 48 hr in medium supplemented with 10 ng/ml IL-1β (Miltenyi), 10 ng/ml TNFα (Miltenyi), 1000 U/ml IL-6 (Miltenyi), and 1 mg/ml PGE2 (Sigma-Aldrich).</p></sec><sec id="s4-3"><title>Generation of stable cell lines</title><p>HeLa TRex Flip-in cells (<xref ref-type="bibr" rid="bib13">Castello et al., 2012</xref>), kindly provided by Professor Matthias Hentze, were co-transfected with pOG44 (3 µg) and pcDNA5-FRT/TO:EF1prom-US28HA or pcDNA5-FRT/TO:EF1prom-US27HA (1 µg) using FuGENE HD transfection reagent (Promega). At 48 hr after transfection, cells were selected by culturing in DMEM (Gibco) supplemented with 10% (v/v) FCS (Sigma-Aldrich), 100 μg/ml streptomycin/100 U/ml penicillin (Gibco), 10 µg/ml blasticidin (Invivogen), 100 µg/ml normocin (Invivogen), and 500 µg/ml geneticin (Invivogen) until cell clones were grown. Successful generation of cells with Doxycycline-inducible expression of US28HA or US27HA was validated by immunoblot analysis.</p></sec><sec id="s4-4"><title>Viruses, infection, and HCMV lysate generation</title><p>Virus stocks from the HCMV strain AD169 (<xref ref-type="bibr" rid="bib53">Le et al., 2008</xref>), AD169-BAC2 (<xref ref-type="bibr" rid="bib54">Le et al., 2011</xref>), AD169-BAC2 ΔUS2-11 (<xref ref-type="bibr" rid="bib104">Zimmermann et al., 2019</xref>), and AD169-BAC20-EGFP (<xref ref-type="bibr" rid="bib57">Le Trilling et al., 2016</xref>) were generated as previously described and propagated in MRC-5 cells (<xref ref-type="bibr" rid="bib37">Hengel et al., 1995</xref>).</p><p>AD169-BAC2-UL131rep was generated by two-step red-mediated recombination of HCMV bacterial artificial chromosome (<xref ref-type="bibr" rid="bib90">Tischer et al., 2006</xref>) using the primers AD169-UL131rep-Kana1 and AD169-UL131rep-Kana2 (<xref ref-type="table" rid="table1">Table 1</xref>) for PCR amplification and AD169-BAC2 as parental BAC. AD169-BAC2rep ΔUS28 was generated according to previously described procedures (<xref ref-type="bibr" rid="bib90">Tischer et al., 2006</xref>; <xref ref-type="bibr" rid="bib98">Wagner et al., 2002</xref>) using AD169-BAC2-UL131rep as parental BAC. Briefly, a PCR fragment was generated using the plasmid pSLFRTKn (<xref ref-type="bibr" rid="bib4">Atalay et al., 2002</xref>) as template and primers ΔUS28-Kana1 and ΔUS28-Kana2 listed in <xref ref-type="table" rid="table1">Table 1</xref>. The PCR fragment containing a kanamycin resistance cassette was inserted into the AD169-BAC2-UL131rep by homologous recombination in <italic>E. coli</italic>, resulting in replacement of the US28 target sequence. Flp-mediated recombination was used to remove the kanamycin resistance cassette flanked by frt sites. Successful mutagenesis was confirmed by PCR analysis. Recombinant HCMV was reconstituted from HCMV BAC DNA by transfection with FuGENE HD transfection reagent (Promega) into permissive MRC-5 cells and further propagation of the virus in ARPE-19 cells.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Primer sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top">Forward</th><th align="left" valign="top">Reverse</th></tr></thead><tbody><tr><td align="left" valign="top">Cloning HCMV-US28HA</td><td align="left" valign="top"><named-content content-type="sequence">CGGCTAGCATGACACCGACGACGACGACC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAA</named-content><break/><named-content content-type="sequence">CATCGTATGGGTACGGTATAATTTGTGA</named-content><break/><named-content content-type="sequence">GACGCG</named-content></td></tr><tr><td align="left" valign="top">Cloning HCMV-US27HA</td><td align="left" valign="top"><named-content content-type="sequence">CGGCTAGCATGACCACCTCTACAAATAATC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAA</named-content><break/><named-content content-type="sequence">CATCGTATGGGTACAACAGAAATTCC</named-content><break/><named-content content-type="sequence">TCCTCCCC</named-content></td></tr><tr><td align="left" valign="top">Cloning HCMV-US29HA</td><td align="left" valign="top"><named-content content-type="sequence">CGGCTAGCATGCGGTGTTTCCGATGGTGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGGAATTCTTAAGCGTAATCTGGAA</named-content><break/><named-content content-type="sequence">CATCGTATGGGTACTCGGAGGTGTCA</named-content><break/><named-content content-type="sequence">ACAACCC</named-content></td></tr><tr><td align="left" valign="top">QuikChange US28-R129A</td><td align="left" valign="top"><named-content content-type="sequence">CACGGAGATTGCACTCGATGCCTACTACGCTATTGTTTAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GTAAACAATAGCGTAGTAGGCATCG</named-content><break/><named-content content-type="sequence">AGTGCAATCTCCGTG</named-content></td></tr><tr><td align="left" valign="top">QuikChange US28-ΔC (Δ298–354)</td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTACTTGGTGCCCACGA</named-content><break/><named-content content-type="sequence">AGACG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGTCTTCGTGGGCACCAAGTACCC</named-content><break/><named-content content-type="sequence">ATACGATGTTCCAGATTACGCTTAAC</named-content><break/><named-content content-type="sequence">TCGAGCG</named-content></td></tr><tr><td align="left" valign="top">QuikChange US28-Δ314–354</td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTAGAGTCGCTGGCGAA</named-content><break/><named-content content-type="sequence">ACTCG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGAGTTTCGCCAGCGACTCTACCCA</named-content><break/><named-content content-type="sequence">TACGATGTTCCAGATTACGCTTAAC</named-content><break/><named-content content-type="sequence">TCGAGCG</named-content></td></tr><tr><td align="left" valign="top">QuikChange US28-Δ330–354</td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTACCGACGCGAA</named-content><break/><named-content content-type="sequence">AAGCTCATGC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCATGAGCTTTTCGCGTCGGTACC</named-content><break/><named-content content-type="sequence">CATACGATGTTCCAGATTACGCTTA</named-content><break/><named-content content-type="sequence">ACTCGAGCG</named-content></td></tr><tr><td align="left" valign="top">QuikChange US28-Δ346–354</td><td align="left" valign="top"><named-content content-type="sequence">CGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTACTCGTCGGACAGCGTGTCG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CGACACGCTGTCCGACGAGTACCC</named-content><break/><named-content content-type="sequence">ATACGATGTTCCAGATTACGCTTAAC</named-content><break/><named-content content-type="sequence">TCGAGCG</named-content></td></tr><tr><td align="left" valign="top">AD169-BAC2-UL131rep-Kana</td><td align="left" valign="top"><named-content content-type="sequence">TGCGCCGTGGTGCTGGGTCAGTG</named-content><break/><named-content content-type="sequence">CCAGCGGGAAACCGCGGAAAAAA</named-content><break/><named-content content-type="sequence">ACGATTATTACC</named-content><named-content content-type="sequence">GAAGGATGACGA</named-content><break/><named-content content-type="sequence">CGATAAGTAGGG</named-content></td><td align="left" valign="top"><named-content content-type="sequence">GCGTCCCAGTAATGCGGTACTCGGT</named-content><break/><named-content content-type="sequence">AATAATCGTTTTTTTCCGCGGTTTCC</named-content><break/><named-content content-type="sequence">CGCTGGCACCAACCAATTAACCAAT</named-content><break/><named-content content-type="sequence">TCTGATTAG</named-content></td></tr><tr><td align="left" valign="top">ΔUS28-Kana</td><td align="left" valign="top"><named-content content-type="sequence">CAGTCTCTCGGTGCGTGGACCAGACGGCGTCCATGCACCGAGGGCA</named-content><break/><named-content content-type="sequence">GAACTGGTGCTATCCCAGTGAATTC</named-content><break/><named-content content-type="sequence">GAGCTCGGTAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CACGGGGAAAAGAGGGGCGGACAC</named-content><break/><named-content content-type="sequence">GGGGTTTGTATGAAAAGGCCGAGGTA</named-content><break/><named-content content-type="sequence">GCGCTTTTTTGACCATGATTACGCCAA</named-content><break/><named-content content-type="sequence">GCTCC</named-content></td></tr><tr><td align="left" valign="top">HLA-DPB1 (<xref ref-type="bibr" rid="bib66">Meurer et al., 2018</xref>)</td><td align="left" valign="top"><named-content content-type="sequence">GCTTCCTGGAGAGATACATC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">CAGCTCGTAGTTGTGTCTGC</named-content></td></tr><tr><td align="left" valign="top">HLA-DR (<xref ref-type="bibr" rid="bib69">Morimoto et al., 2004</xref>)</td><td align="left" valign="top"><named-content content-type="sequence">GCCAACCTGGAAATCATGAC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">AGGGCTGTTCGTGAGCACA</named-content></td></tr><tr><td align="left" valign="top">CIITA (<xref ref-type="bibr" rid="bib76">Sandhu and Buchkovich, 2020</xref>)</td><td align="left" valign="top"><named-content content-type="sequence">AGCCTTTCAAAGCCAAGTCC</named-content></td><td align="left" valign="top"><named-content content-type="sequence">TTGTTCTCACTCAGCGCATC</named-content></td></tr></tbody></table></table-wrap><p>Viral titers were determined by standard plaque titration on MRC-5 cells. All infections were conducted with centrifugal enhancement (900 g for 30 min).</p><p>For generation of HCMV lysates for T cell stimulation, BJ-5ta cells were infected with AD169-BAC2 at an MOI of 3 or mock-treated. At 4 d post-infection, cells were scraped, washed, and resuspended in PBS. After five freeze-thaw cycles, lysates were treated with ultra-sonication (two times 10 s) and centrifuged (1000 g, 20 min, 4 °C). Supernatants were used for T cell culture assays.</p></sec><sec id="s4-5"><title>Treatment with cytokines and inhibitors</title><p>Human IFNγ (PBL), IFNα (PBL), and TNFα (PeproTech) were used in the following concentrations: 200 U/ml, 200 U/ml, and 20 ng/ml, respectively.</p><p>Doxycycline (200 ng/µl, Sigma) was used to induce expression of the transgenes in HeLa TRex Flip-in:US28HA and HeLa TRex Flip-in:US27HA cells.</p><p>The following inhibitors were used to target different cellular degradation pathways: MG-132 (10 µM; Sigma-Aldrich), MLN4924 (2.5 µM; Active Biochem), TAS4464 (1 µM; MedChemExpress), Bortezomib (1 µM; Sellekchem), 3-Methyladenine (10 mM; Sigma-Aldrich), Bafilomycin (1 µM; Tocris), Chloroquine (50 µM; Sigma-Aldrich), Ammonium chloride (5 mM; Sigma-Aldrich), Z-VAD-FMK (50 µM; R&amp;D), Pepstatin A (10 µM; Roth), E-64 (5 µM; Sigma-Aldrich), PMSF (1 mM; Roth), Protease Inhibitor Cocktail (1:200; Sigma-Aldrich), Dynasore (100 µM; MedChemExpress), or Decanoyl-RVKR-CMK (10 µM; Sigma-Aldrich).</p></sec><sec id="s4-6"><title>Protein stability determination by cycloheximide chase assay</title><p>Protein stability was determined in transfected HeLa cells (see transfection, plasmids, and mutagenesis) by treatment with 50 µg/ml cycloheximide (CHX, Roth). Cells were washed once in CHX-containing medium, followed by incubation in CHX-containing medium for indicated time periods. Finally, whole cell lysates were prepared and subjected to immunoblot analysis.</p></sec><sec id="s4-7"><title>Protein precipitation of cell culture supernatant</title><p>Cell culture supernatant of transiently transfected HeLa cells (see transfection, plasmids and mutagenesis) was collected. 400 µl supernatant were mixed with 1600 µl ice-cold acetone and incubated for 1 hr at –20 °C. After centrifugation for 90 min, 4 °C, and 13,000 g, the pellet was dried and resuspended in RIPA buffer. Subsequently, samples were subjected to immunoblot analysis.</p></sec><sec id="s4-8"><title>Transfection, plasmids, and mutagenesis</title><p>Transient transfection was performed using 1 or 2 µg plasmid DNA and 3.5 or 7 µl FuGENE HD transfection reagent (Promega) per 5×10<sup>5</sup> cells. Cells were transfected with the following plasmids: pUNO1-hCIITA (Invitrogen), pRP-humanCIITA-3xFLAG (VectorBuilder), pRP-3xFLAG-mouseCIITA (VectorBuilder), pcDNA3.1(+) (Invitrogen), pIRES<sub>neo</sub>-FLAG/HA-EYFP (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:Addgene_10825">Addgene_10825</ext-link>, Gift from Thomas Tuschl <xref ref-type="bibr" rid="bib64">Meister et al., 2004</xref>), pOG44 (Invitrogen), and HCMV ORF Expression Library (<xref ref-type="bibr" rid="bib75">Salsman et al., 2008</xref>). Following plasmids were generated in this study: pcDNA3.1:US28HA, pcDNA3.1:US28HA-R129A, pcDNA3.1:US28HA-ΔC (Δ298–354), pIRES2-EGFP:US28HA, pIRES2-EGFP:US28HA-1–297, pIRES2-EGFP:US28HA-1–313, pIRES2-EGFP:US28HA-1–329, pIRES2-EGFP:US28HA-1–345, pcDNA3.1:US27HA, pcDNA3.1:US29HA, pcDNA5-FRT/TO:EF1prom:US28HA, and pcDNA5-FRT/TO:EF1prom:US27HA.</p><p>Cloning of pcDNA3.1:US28HA, pcDNA3.1:US27HA, and pcDNA3.1:US29HA was performed using the primers listed in <xref ref-type="table" rid="table1">Table 1</xref>. In order to generate US28 mutants, QuikChangeII XL Site-Directed Mutagenesis kit (Agilent Technologies) was used according to the manufacturer’s instructions with pcDNA3.1-US28HA plasmid as the template DNA and respective primers (see <xref ref-type="table" rid="table1">Table 1</xref>). Cloning of pIRES2-EGFP and pcDNA5-FRT/TO:EF1prom constructs was performed by subcloning the respective gene sequences from the pcDNA3.1 constructs. All constructs were confirmed by DNA sequencing of the insert (LGC Genomics).</p></sec><sec id="s4-9"><title>Immunoblot analysis</title><p>For immunoblotting, whole cell lysates were prepared as described before in RIPA (<xref ref-type="bibr" rid="bib92">Trilling et al., 2009</xref>) or 5 M urea buffer and equal amounts of protein were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were subsequently transferred onto nitrocellulose membranes and immunoblot analysis was performed with the following antibodies: HA (Sigma-Aldrich, H6908), FLAG (M2, Sigma-Aldrich, F3165), β-tubulin (Cell Signaling, 2146), β-actin (Sigma-Aldrich, A2228), GAPDH (FL-335, Santa Cruz, sc-25778). Proteins were visualized using peroxidase-coupled secondary antibodies (rabbit-POD, Sigma-Aldrich, A6154; mouse-POD, Jackson ImmunoResearch, 115-035-062) and an enhanced chemiluminescence system (Cell Signaling Technology).</p></sec><sec id="s4-10"><title>Immunoprecipitation</title><p>Cells were lysed (150 mM NaCl, 10 mM KCl, 10 mM MgCl<sub>2</sub>, 10% [v/v] glycerol, 20 mM HEPES [pH 7.4], 0.5% [v/v] NP-40, 0.1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM dithiothreitol [DTT], 10 µM pepstatin A, 5 µM leupeptin, 0.1 mM Na-vanadate, Complete protease inhibitor EDTA-free [Roche]). Lysates were centrifuged and immunoprecipitation (IP) antibody (anti-HA, HA-7, Sigma-Aldrich, H3663, or anti-FLAG, M2, Sigma-Aldrich, F3165) was added to the supernatant. Precipitation of immune complexes was performed with protein G-sepherose (GE Healthcare), benzonase (Sigma-Aldrich, E1014) digestion for 3 hr at 4 °C, and washing steps with 150, 250, and 500 mM NaCl-containing buffer. Samples were further processed by immunoblot analysis.</p></sec><sec id="s4-11"><title>Semi-quantitative RT-PCR</title><p>For semi-quantitative RT-PCR, total RNA was isolated from 1×10<sup>6</sup> cells using the RNeasy Mini kit (Qiagen) and digested with DNase I. Subsequent one-step RT-PCR (Qiagen) was performed using gene-specific primers listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s4-12"><title>Flow cytometry</title><p>For flow cytometry, cells were detached, washed with 2% FCS-PBS, and stained with labeled antibodies. For intracytoplasmic staining, cells were fixed in 4% PFA-PBS for 15 min at room temperature after detachment and washing steps. Permeabilization was performed with 1% saponin-PBS for 15 min at room temperature, followed by antibody staining. The following antibodies were used: HLA-DP-BV421 (B7/21, BD Biosciences, 750875), HLA-DP-APC (B7/21, Leinco Technologies, H240), HLA-DP-PE (B7/21, BD Biosciences, 566825), HLA-DR-PE (L243, BD Biosciences, 347401), HLA-DQ-PE (HLADQ1, BioLegend, 318106), HLA-DM-PE (MaP.DM1, BD Biosciences, 555983), CD137-APC (4B4-1, BD Biosciences, 561702), CD4-PE-Cy7 (SK3, BD Biosciences, 557852), CD8-Pacific Blue (B9.11, Beckman Coulter, B49182), CD3-Krome Orange (UCHT1, Beckman Coulter, B00068), CD57-FITC (TB03, Miltenyi Biotec, 130-122-935), CD14-FITC (MφP9, BD Biosciences, 345784), CD19-APC (HIB19, BD Biosciences, 555415), CD56-PE (N901, Beckman Coulter, A07788). Measurements were performed in a Gallios 10/3 cytometer (Beckman Coulter), using the Kaluza for Gallios Acquisition software (Version 1.0, Beckman Coulter), or a BD FACSCanto II (BD Biosciences), using BD FACSDiva software (BD Biosciences). Data analysis was conducted with FlowJow (Version 10.8.1, Tree Star).</p></sec><sec id="s4-13"><title>T cell activation assay</title><p>To obtain HCMV-specific CD4 + T cells, PBMCs were pulsed with HCMV lysate (25 µg/ml) for 4 hr at 37 °C in 5% CO<sub>2</sub>. Cells were cultured for 14 d in RPMI 1640 (ccpro) supplemented with 10% heat-inactivated human serum (Merck), 10 ng/ml IL-7, 1 ng/ml IL-12, and 5 ng/ml IL-15 (R&amp;D Systems). Re-stimulation with irradiated (100 Gy), lysate-pulsed PBMCs was performed at day 7 of the co-culture. Afterwards, cells were cultured in RPMI 1640 (c.c.pro) supplemented with 10% heat-inactivated human serum (Merck), 50 U/ml IL-2 (Miltenyi), 10 ng/ml IL-7 and 5 ng/ml IL-15 (R&amp;D Systems). After 14 d, expanded T cells were re-challenged for 24 hr with HeLa cells transfected with the respective plasmids and pulsed with mock or HCMV lysate (25 µg/ml). The specific T cell response was quantified by flow cytometry as a percentage of gated CD4 + T cells expressing the activation marker CD137 as previously described (<xref ref-type="bibr" rid="bib66">Meurer et al., 2018</xref>).</p></sec><sec id="s4-14"><title>Antiviral activity of T cell supernatant</title><p>To evaluate the antiviral activity of supernatants from the T cell activation assay, MRC-5 cells were incubated with these supernatants in serial dilutions for 24 hr before cells were infected with HCMV-BAC20-EGFP at an MOI of 0.05. HCMV-induced EGFP expression was quantified using a Mithras<sup>2</sup> LB 943 Multimode Reader (Berthold Technologies, Software MikroWin 2010). Microscopy was conducted with a Leica DM IL LED Microscope (Software LAS V4.0) and a Bioreader-7000 Fz (BIO-SYS, Software EazyReader).</p></sec><sec id="s4-15"><title>LS-MS/MS sample preparation</title><p>Cell lysates were processed according to the SP3 protocol (<xref ref-type="bibr" rid="bib38">Hughes et al., 2019</xref>) with minor modifications. Briefly, the cells were lysed in urea buffer (7 M urea, 2 M thiourea, 30 mM TRIS, 0.1% sodium deoxycholate, pH 8.5) and an aliquot of 10 µg was reduced with dithiothreitol (5 mM final concentration, 50 °C, 15 min), and alkylated using 2-iodoacetamide (15 mM final concentration, RT, 15 min). Subsequently, 100 µg of SP3-beads were added and the volume was adjusted to 100 µL using 50 mM ammonium bicarbonate (ambic). 170 µL of acetonitrile (ACN) were added and samples were incubated for 18 min. After washing the beads twice with 180 µL 70% EtOH and once with 180 µL ACN, 1 µg trypsin (SERVA Electrophoresis, Heidelberg, Germany) in 55 µL ambic was added and samples were digested overnight at 37 °C. Finally, the solution was transferred to a new vial, evaporated to dryness, and peptides were resuspended in 100 µL 0.1% trifluoracetic acid.</p></sec><sec id="s4-16"><title>Data-independent acquisition mass spectrometry</title><p>300 ng tryptic peptides per sample were analyzed in randomized order using a Vanquish Neo UHPLC coupled to an Orbitrap 480 mass spectrometer (both Thermo Scientific). The mobile phase A consisted of 0.1% formic acid (FA), mobile phase B of 80% ACN, and 0.1% FA. Peptides were loaded on a trap column (Acclaim PepMap 100, 100 µm × 2 cm, Thermo Scientific) using combined control with a loading volume of 20 µL, a maximum flow rate of 30 µL/min and a maximum pressure of 800 bar. Separation of peptides was achieved using a DNV PepMap Neo separation column (75 µm × 150 mm, Thermo Scientific) and a gradient from 1–40% B within 120 min and a flow rate of 400 nL/min at 60 °C. The MS parameters were set as follows: The RF lens amplitude was set to 55%, the MS1 scan range was 350–1450 m/z with a resolution of 120,000, a normalized AGC target of 300% and a maximum injection time of 54 ms. MS2 scans were acquired using a resolution of 30,000, a HCD collision energy of 30%, and a scan rage of 145–1450 with a normalized AGC target of 2500% and a maximum injection time of 80ms. A total of 40 isolation windows between 350 and 1450 m/z were cycled through with one MS1 scan being recorded after every 21 MS2 scans.</p></sec><sec id="s4-17"><title>Mass spectrometry data analysis</title><p>Protein identification and quantification was conducted using DIA-NN (v.1.8.1; <xref ref-type="bibr" rid="bib20">Demichev et al., 2020</xref>) in library-free mode. The SwissProt database restricted to <italic>Homo sapiens</italic> as well as the Uniprot reference proteome for the Human cytomegalovirus (both ver. 2022_02) were used for peptide identification. Default settings were used, except for the neural network classifier, which was used in double-pass mode, and protein inference, which was set to species-specific. The report file was filtered for all q-values≤0.01 using R (ver. 4.3.0; <ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>). Subsequently, protein quantities were calculated using the MaxLFQ algorithm as implemented in the DIA-NN R package. Missing data was imputed on protein level using the mixed imputation function from the imp4p package (<xref ref-type="bibr" rid="bib31">Gianetto et al., 2020</xref>). Statistically significant differences between the experimental groups were assessed by means of ANOVA followed by Tukey’s HSD post hoc tests. The ANOVA p-value was corrected for multiple testing according to the method of Benjamini-Hochberg. The significance threshold was set to pFDR ≤0.05, p posthoc ≤0.05 and a ratio of mean intensities ≥2 or ≤0.5.</p></sec><sec id="s4-18"><title>Quantification and statistical analysis</title><p>The resulting data were analyzed using GraphPad Prism software. The values are reported as Mean ± standard deviation (SD). Statistical significance was tested by applying the respective test indicated in the figure legends.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Data curation, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: PBMCs were obtained from healthy blood donors from the University Hospital Essen after informed consent under Ethical Review Board approvals 14-5961-BO and 16-6769-BO, in accordance with the Declaration of Helsinki.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Global proteome analysis data.</title></caption><media xlink:href="elife-96414-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96414-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Matthias Hentze for kindly providing the HeLa TRex Flip-in cell line, Lejla Timmer, Kerstin von Ameln, and Sophie Eppler for excellent technical support, as well as the teams of the Fleischhauer and Trilling laboratories for insightful discussions. MT received funding from the Deutsche Forschungsgemeinschaft (DFG) through grants TR 1208/1–1 and TR 1208/2–1. KF received funding from the DFG through grant FL 843/1–1, the Deutsche José Carreras Leukämie Stiftung (DJCLS 20 R/2019), the Dr. Werner Jackstädt Stiftung, and the Joseph Senker Stiftung. We also acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ameres</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Wiesner</surname><given-names>M</given-names></name><name><surname>Mautner</surname><given-names>J</given-names></name><name><surname>Moosmann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A diverse repertoire of cd4 t cells targets the immediate-early 1 protein of human cytomegalovirus</article-title><source>Frontiers in Immunology</source><volume>6</volume><elocation-id>598</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2015.00598</pub-id><pub-id pub-id-type="pmid">26635812</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrieta-Bolaños</surname><given-names>E</given-names></name><name><surname>Crivello</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gadalla</surname><given-names>SM</given-names></name><name><surname>Paczesny</surname><given-names>S</given-names></name><name><surname>Marsh</surname><given-names>SGE</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Spellman</surname><given-names>SR</given-names></name><name><surname>Bolon</surname><given-names>Y-T</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation</article-title><source>Blood</source><volume>140</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1182/blood.2022015708</pub-id><pub-id pub-id-type="pmid">35609150</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashley</surname><given-names>CL</given-names></name><name><surname>McSharry</surname><given-names>BP</given-names></name><name><surname>McWilliam</surname><given-names>HEG</given-names></name><name><surname>Stanton</surname><given-names>RJ</given-names></name><name><surname>Fielding</surname><given-names>CA</given-names></name><name><surname>Mathias</surname><given-names>RA</given-names></name><name><surname>Fairlie</surname><given-names>DP</given-names></name><name><surname>McCluskey</surname><given-names>J</given-names></name><name><surname>Villadangos</surname><given-names>JA</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Abendroth</surname><given-names>A</given-names></name><name><surname>Slobedman</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Suppression of MR1 by human cytomegalovirus inhibits MAIT cell activation</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1107497</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1107497</pub-id><pub-id pub-id-type="pmid">36845106</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atalay</surname><given-names>R</given-names></name><name><surname>Zimmermann</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Borst</surname><given-names>E</given-names></name><name><surname>Benz</surname><given-names>C</given-names></name><name><surname>Messerle</surname><given-names>M</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs</article-title><source>Journal of Virology</source><volume>76</volume><fpage>8596</fpage><lpage>8608</lpage><pub-id pub-id-type="doi">10.1128/jvi.76.17.8596-8608.2002</pub-id><pub-id pub-id-type="pmid">12163579</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beisser</surname><given-names>PS</given-names></name><name><surname>Laurent</surname><given-names>L</given-names></name><name><surname>Virelizier</surname><given-names>JL</given-names></name><name><surname>Michelson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Human cytomegalovirus chemokine receptor gene US28 is transcribed in latently infected THP-1 monocytes</article-title><source>Journal of Virology</source><volume>75</volume><fpage>5949</fpage><lpage>5957</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.13.5949-5957.2001</pub-id><pub-id pub-id-type="pmid">11390596</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bialas</surname><given-names>KM</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Tran</surname><given-names>D</given-names></name><name><surname>Varner</surname><given-names>V</given-names></name><name><surname>Cisneros De La Rosa</surname><given-names>E</given-names></name><name><surname>Chiuppesi</surname><given-names>F</given-names></name><name><surname>Wussow</surname><given-names>F</given-names></name><name><surname>Kattenhorn</surname><given-names>L</given-names></name><name><surname>Macri</surname><given-names>S</given-names></name><name><surname>Kunz</surname><given-names>EL</given-names></name><name><surname>Estroff</surname><given-names>JA</given-names></name><name><surname>Kirchherr</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Lauck</surname><given-names>M</given-names></name><name><surname>O’Connor</surname><given-names>DH</given-names></name><name><surname>Hall</surname><given-names>AHS</given-names></name><name><surname>Xavier</surname><given-names>A</given-names></name><name><surname>Diamond</surname><given-names>DJ</given-names></name><name><surname>Barry</surname><given-names>PA</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Permar</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission</article-title><source>PNAS</source><volume>112</volume><fpage>13645</fpage><lpage>13650</lpage><pub-id pub-id-type="doi">10.1073/pnas.1511526112</pub-id><pub-id pub-id-type="pmid">26483473</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billstrom</surname><given-names>MA</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name><name><surname>Avdi</surname><given-names>NJ</given-names></name><name><surname>Worthen</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection</article-title><source>Journal of Virology</source><volume>72</volume><fpage>5535</fpage><lpage>5544</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.7.5535-5544.1998</pub-id><pub-id pub-id-type="pmid">9621010</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodaghi</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Zipeto</surname><given-names>D</given-names></name><name><surname>Vita</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Laurent</surname><given-names>L</given-names></name><name><surname>Arenzana-Seisdedos</surname><given-names>F</given-names></name><name><surname>Virelizier</surname><given-names>JL</given-names></name><name><surname>Michelson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells</article-title><source>The Journal of Experimental Medicine</source><volume>188</volume><fpage>855</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1084/jem.188.5.855</pub-id><pub-id pub-id-type="pmid">9730887</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bongers</surname><given-names>G</given-names></name><name><surname>Maussang</surname><given-names>D</given-names></name><name><surname>Muniz</surname><given-names>LR</given-names></name><name><surname>Noriega</surname><given-names>VM</given-names></name><name><surname>Fraile-Ramos</surname><given-names>A</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Marchesi</surname><given-names>F</given-names></name><name><surname>Thirunarayanan</surname><given-names>N</given-names></name><name><surname>Vischer</surname><given-names>HF</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Mayer</surname><given-names>L</given-names></name><name><surname>Harpaz</surname><given-names>N</given-names></name><name><surname>Leurs</surname><given-names>R</given-names></name><name><surname>Furtado</surname><given-names>GC</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Tortorella</surname><given-names>D</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>3969</fpage><lpage>3978</lpage><pub-id pub-id-type="doi">10.1172/JCI42563</pub-id><pub-id pub-id-type="pmid">20978345</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boss</surname><given-names>JM</given-names></name><name><surname>Jensen</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transcriptional regulation of the MHC class II antigen presentation pathway</article-title><source>Current Opinion in Immunology</source><volume>15</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/s0952-7915(02)00015-8</pub-id><pub-id pub-id-type="pmid">12495741</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodin</surname><given-names>P</given-names></name><name><surname>Jojic</surname><given-names>V</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Angel</surname><given-names>CJL</given-names></name><name><surname>Furman</surname><given-names>D</given-names></name><name><surname>Shen-Orr</surname><given-names>S</given-names></name><name><surname>Dekker</surname><given-names>CL</given-names></name><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Butte</surname><given-names>AJ</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name><name><surname>Davis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Variation in the human immune system is largely driven by non-heritable influences</article-title><source>Cell</source><volume>160</volume><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.12.020</pub-id><pub-id pub-id-type="pmid">25594173</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burg</surname><given-names>JS</given-names></name><name><surname>Ingram</surname><given-names>JR</given-names></name><name><surname>Venkatakrishnan</surname><given-names>AJ</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Dukkipati</surname><given-names>A</given-names></name><name><surname>Feinberg</surname><given-names>EN</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Waghray</surname><given-names>D</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor</article-title><source>Science</source><volume>347</volume><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1126/science.aaa5026</pub-id><pub-id pub-id-type="pmid">25745166</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castello</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Eichelbaum</surname><given-names>K</given-names></name><name><surname>Horos</surname><given-names>R</given-names></name><name><surname>Beckmann</surname><given-names>BM</given-names></name><name><surname>Strein</surname><given-names>C</given-names></name><name><surname>Davey</surname><given-names>NE</given-names></name><name><surname>Humphreys</surname><given-names>DT</given-names></name><name><surname>Preiss</surname><given-names>T</given-names></name><name><surname>Steinmetz</surname><given-names>LM</given-names></name><name><surname>Krijgsveld</surname><given-names>J</given-names></name><name><surname>Hentze</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Insights into RNA biology from an atlas of mammalian mRNA-binding proteins</article-title><source>Cell</source><volume>149</volume><fpage>1393</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.031</pub-id><pub-id pub-id-type="pmid">22658674</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Class II transactivator regulates the expression of multiple genes involved in antigen presentation</article-title><source>The Journal of Experimental Medicine</source><volume>181</volume><fpage>765</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1084/jem.181.2.765</pub-id><pub-id pub-id-type="pmid">7836928</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chee</surname><given-names>MS</given-names></name><name><surname>Satchwell</surname><given-names>SC</given-names></name><name><surname>Preddie</surname><given-names>E</given-names></name><name><surname>Weston</surname><given-names>KM</given-names></name><name><surname>Barrell</surname><given-names>BG</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Human cytomegalovirus encodes three G protein-coupled receptor homologues</article-title><source>Nature</source><volume>344</volume><fpage>774</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/344774a0</pub-id><pub-id pub-id-type="pmid">2158627</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AKL</given-names></name><name><surname>Abendroth</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>AL</given-names></name><name><surname>Slobedman</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells</article-title><source>Blood</source><volume>108</volume><fpage>3691</fpage><lpage>3699</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-12-026682</pub-id><pub-id pub-id-type="pmid">16931631</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-García</surname><given-names>M</given-names></name><name><surname>Ataya</surname><given-names>M</given-names></name><name><surname>Moraru</surname><given-names>M</given-names></name><name><surname>Vilches</surname><given-names>C</given-names></name><name><surname>López-Botet</surname><given-names>M</given-names></name><name><surname>Muntasell</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human cytomegalovirus antigen presentation by HLA-DR+ NKG2C+ adaptive NK cells specifically activates polyfunctional effector memory CD4+ T lymphocytes</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>687</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00687</pub-id><pub-id pub-id-type="pmid">31001281</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>LB</given-names></name><name><surname>Caposio</surname><given-names>P</given-names></name><name><surname>Kreklywich</surname><given-names>C</given-names></name><name><surname>Pham</surname><given-names>AH</given-names></name><name><surname>Hancock</surname><given-names>MH</given-names></name><name><surname>Jones</surname><given-names>TA</given-names></name><name><surname>Smith</surname><given-names>PP</given-names></name><name><surname>Yurochko</surname><given-names>AD</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name><name><surname>Streblow</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human cytomegalovirus US28 ligand binding activity is required for latency in CD34<sup>+</sup> hematopoietic progenitor cells and humanized NSG Mice</article-title><source>mBio</source><volume>10</volume><elocation-id>e01889-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.01889-19</pub-id><pub-id pub-id-type="pmid">31431555</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>ZB</given-names></name><name><surname>Cooley</surname><given-names>SA</given-names></name><name><surname>Cichocki</surname><given-names>F</given-names></name><name><surname>Felices</surname><given-names>M</given-names></name><name><surname>Wangen</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>DeFor</surname><given-names>TE</given-names></name><name><surname>Bryceson</surname><given-names>YT</given-names></name><name><surname>Diamond</surname><given-names>DJ</given-names></name><name><surname>Brunstein</surname><given-names>C</given-names></name><name><surname>Blazar</surname><given-names>BR</given-names></name><name><surname>Wagner</surname><given-names>JE</given-names></name><name><surname>Weisdorf</surname><given-names>DJ</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Guethlein</surname><given-names>LA</given-names></name><name><surname>Parham</surname><given-names>P</given-names></name><name><surname>Verneris</surname><given-names>MR</given-names></name><name><surname>Miller</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Adaptive natural killer cell and killer cell immunoglobulin-like receptor-expressing T cell responses are induced by cytomegalovirus and are associated with protection against cytomegalovirus reactivation after allogeneic donor hematopoietic cell transplantation</article-title><source>Biology of Blood and Marrow Transplantation</source><volume>21</volume><fpage>1653</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2015.05.025</pub-id><pub-id pub-id-type="pmid">26055301</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demichev</surname><given-names>V</given-names></name><name><surname>Messner</surname><given-names>CB</given-names></name><name><surname>Vernardis</surname><given-names>SI</given-names></name><name><surname>Lilley</surname><given-names>KS</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput</article-title><source>Nature Methods</source><volume>17</volume><fpage>41</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0638-x</pub-id><pub-id pub-id-type="pmid">31768060</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Ehninger</surname><given-names>G</given-names></name><name><surname>Steidle</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>I</given-names></name><name><surname>Bihler</surname><given-names>S</given-names></name><name><surname>Gerneth</surname><given-names>F</given-names></name><name><surname>Vallbracht</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Waller</surname><given-names>HD</given-names></name><name><surname>Müller</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation</article-title><source>Blood</source><volume>82</volume><fpage>1672</fpage><lpage>1678</lpage><pub-id pub-id-type="pmid">8395913</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>EG</given-names></name><name><surname>Krishna</surname><given-names>BA</given-names></name><name><surname>Williamson</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>EY</given-names></name><name><surname>Poole</surname><given-names>E</given-names></name><name><surname>Sedikides</surname><given-names>GX</given-names></name><name><surname>Wills</surname><given-names>M</given-names></name><name><surname>O’Connor</surname><given-names>CM</given-names></name><name><surname>Lehner</surname><given-names>PJ</given-names></name><name><surname>Sinclair</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interferon-responsive genes are targeted during the establishment of human cytomegalovirus latency</article-title><source>mBio</source><volume>10</volume><elocation-id>e02574-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02574-19</pub-id><pub-id pub-id-type="pmid">31796538</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elhasid</surname><given-names>R</given-names></name><name><surname>Etzioni</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Major histocompatibility complex class II deficiency: a clinical review</article-title><source>Blood Reviews</source><volume>10</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/s0268-960x(96)90008-9</pub-id><pub-id pub-id-type="pmid">9012922</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>HE</given-names></name><name><surname>Abraham</surname><given-names>AM</given-names></name><name><surname>Cardin</surname><given-names>RD</given-names></name><name><surname>Mølleskov-Jensen</surname><given-names>A-S</given-names></name><name><surname>Rosenkilde</surname><given-names>MM</given-names></name><name><surname>Davis-Poynter</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of common mechanisms by which human and mouse cytomegalovirus seven-transmembrane receptor homologues contribute to in vivo phenotypes in a mouse model</article-title><source>Journal of Virology</source><volume>87</volume><fpage>4112</fpage><lpage>4117</lpage><pub-id pub-id-type="doi">10.1128/JVI.03406-12</pub-id><pub-id pub-id-type="pmid">23345521</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischhauer</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>BE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities</article-title><source>Blood</source><volume>130</volume><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-03-742346</pub-id><pub-id pub-id-type="pmid">28667011</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>K</given-names></name><name><surname>Mucha</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Lewandowski</surname><given-names>W</given-names></name><name><surname>Kaczanowska</surname><given-names>M</given-names></name><name><surname>Grys</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Natenshon</surname><given-names>A</given-names></name><name><surname>Talarico</surname><given-names>C</given-names></name><name><surname>Buck</surname><given-names>PO</given-names></name><name><surname>Diaz-Decaro</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development</article-title><source>BMC Public Health</source><volume>22</volume><elocation-id>1659</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-022-13971-7</pub-id><pub-id pub-id-type="pmid">36050659</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabanti</surname><given-names>E</given-names></name><name><surname>Lilleri</surname><given-names>D</given-names></name><name><surname>Ripamonti</surname><given-names>F</given-names></name><name><surname>Bruno</surname><given-names>F</given-names></name><name><surname>Zelini</surname><given-names>P</given-names></name><name><surname>Furione</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>AA</given-names></name><name><surname>Alessandrino</surname><given-names>EP</given-names></name><name><surname>Gerna</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reconstitution of human cytomegalovirus-specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection</article-title><source>Biology of Blood and Marrow Transplantation</source><volume>21</volume><fpage>2192</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2015.08.002</pub-id><pub-id pub-id-type="pmid">26260678</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamadia</surname><given-names>LE</given-names></name><name><surname>Rentenaar</surname><given-names>RJ</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name><name><surname>ten Berge</surname><given-names>IJM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Properties of CD4(+) T cells in human cytomegalovirus infection</article-title><source>Human Immunology</source><volume>65</volume><fpage>486</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2004.02.020</pub-id><pub-id pub-id-type="pmid">15172448</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Kuhns</surname><given-names>DB</given-names></name><name><surname>Tiffany</surname><given-names>HL</given-names></name><name><surname>McDermott</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor</article-title><source>The Journal of Experimental Medicine</source><volume>177</volume><fpage>1421</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1084/jem.177.5.1421</pub-id><pub-id pub-id-type="pmid">7683036</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>28539</fpage><lpage>28542</lpage><pub-id pub-id-type="pmid">7961796</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Gianetto</surname><given-names>QG</given-names></name><name><surname>Wieczorek</surname><given-names>S</given-names></name><name><surname>Couté</surname><given-names>Y</given-names></name><name><surname>Burger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Peptide-Level Multiple Imputation Strategy Accounting for the Different Natures of Missing Values in Proteomics Data</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.05.29.122770</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil</surname><given-names>MP</given-names></name><name><surname>Bohn</surname><given-names>E</given-names></name><name><surname>O’Guin</surname><given-names>AK</given-names></name><name><surname>Ramana</surname><given-names>CV</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Stark</surname><given-names>GR</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Biologic consequences of Stat1-independent IFN signaling</article-title><source>PNAS</source><volume>98</volume><fpage>6680</fpage><lpage>6685</lpage><pub-id pub-id-type="doi">10.1073/pnas.111163898</pub-id><pub-id pub-id-type="pmid">11390995</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodrum</surname><given-names>FD</given-names></name><name><surname>Jordan</surname><given-names>CT</given-names></name><name><surname>High</surname><given-names>K</given-names></name><name><surname>Shenk</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency</article-title><source>PNAS</source><volume>99</volume><fpage>16255</fpage><lpage>16260</lpage><pub-id pub-id-type="doi">10.1073/pnas.252630899</pub-id><pub-id pub-id-type="pmid">12456880</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>P</given-names></name><name><surname>Reeves</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pathogenesis of human cytomegalovirus in the immunocompromised host</article-title><source>Nature Reviews. Microbiology</source><volume>19</volume><fpage>759</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00582-z</pub-id><pub-id pub-id-type="pmid">34168328</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>NR</given-names></name><name><surname>Tomazin</surname><given-names>RA</given-names></name><name><surname>Wisner</surname><given-names>TW</given-names></name><name><surname>Dunn</surname><given-names>C</given-names></name><name><surname>Boname</surname><given-names>JM</given-names></name><name><surname>Lewinsohn</surname><given-names>DM</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation</article-title><source>Journal of Virology</source><volume>76</volume><fpage>10929</fpage><lpage>10941</lpage><pub-id pub-id-type="doi">10.1128/jvi.76.21.10929-10941.2002</pub-id><pub-id pub-id-type="pmid">12368336</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>NR</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells</article-title><source>Journal of Virology</source><volume>77</volume><fpage>9287</fpage><lpage>9294</lpage><pub-id pub-id-type="doi">10.1128/jvi.77.17.9287-9294.2003</pub-id><pub-id pub-id-type="pmid">12915544</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Esslinger</surname><given-names>C</given-names></name><name><surname>Pool</surname><given-names>J</given-names></name><name><surname>Goulmy</surname><given-names>E</given-names></name><name><surname>Koszinowski</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells</article-title><source>The Journal of General Virology</source><volume>76 (Pt 12)</volume><fpage>2987</fpage><lpage>2997</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-76-12-2987</pub-id><pub-id pub-id-type="pmid">8847504</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>CS</given-names></name><name><surname>Moggridge</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>T</given-names></name><name><surname>Sorensen</surname><given-names>PH</given-names></name><name><surname>Morin</surname><given-names>GB</given-names></name><name><surname>Krijgsveld</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Single-pot, solid-phase-enhanced sample preparation for proteomics experiments</article-title><source>Nature Protocols</source><volume>14</volume><fpage>68</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0082-x</pub-id><pub-id pub-id-type="pmid">30464214</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyun</surname><given-names>YS</given-names></name><name><surname>Jo</surname><given-names>HA</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Baek</surname><given-names>IC</given-names></name><name><surname>Sohn</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>HI</given-names></name><name><surname>Kim</surname><given-names>TG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Comprehensive analysis of CD4<sup>+</sup> T cell responses to CMV pp65 antigen restricted by single HLA-DR, -DQ, and -DP allotype within an individual</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>602014</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.602014</pub-id><pub-id pub-id-type="pmid">33658991</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonjić</surname><given-names>S</given-names></name><name><surname>Mutter</surname><given-names>W</given-names></name><name><surname>Weiland</surname><given-names>F</given-names></name><name><surname>Reddehase</surname><given-names>MJ</given-names></name><name><surname>Koszinowski</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes</article-title><source>The Journal of Experimental Medicine</source><volume>169</volume><fpage>1199</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1084/jem.169.4.1199</pub-id><pub-id pub-id-type="pmid">2564415</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonjić</surname><given-names>S</given-names></name><name><surname>Pavić</surname><given-names>I</given-names></name><name><surname>Lucin</surname><given-names>P</given-names></name><name><surname>Rukavina</surname><given-names>D</given-names></name><name><surname>Koszinowski</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes</article-title><source>Journal of Virology</source><volume>64</volume><fpage>5457</fpage><lpage>5464</lpage><pub-id pub-id-type="doi">10.1128/JVI.64.11.5457-5464.1990</pub-id><pub-id pub-id-type="pmid">1976821</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juno</surname><given-names>JA</given-names></name><name><surname>van Bockel</surname><given-names>D</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Kelleher</surname><given-names>AD</given-names></name><name><surname>Zaunders</surname><given-names>JJ</given-names></name><name><surname>Munier</surname><given-names>CML</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cytotoxic CD4 T cells-friend or foe during viral infection?</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00019</pub-id><pub-id pub-id-type="pmid">28167943</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamatani</surname><given-names>Y</given-names></name><name><surname>Wattanapokayakit</surname><given-names>S</given-names></name><name><surname>Ochi</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Hosono</surname><given-names>N</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Tsunoda</surname><given-names>T</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Kumada</surname><given-names>H</given-names></name><name><surname>Puseenam</surname><given-names>A</given-names></name><name><surname>Sura</surname><given-names>T</given-names></name><name><surname>Daigo</surname><given-names>Y</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Chantratita</surname><given-names>W</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians</article-title><source>Nature Genetics</source><volume>41</volume><fpage>591</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/ng.348</pub-id><pub-id pub-id-type="pmid">19349983</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiritsy</surname><given-names>MC</given-names></name><name><surname>Ankley</surname><given-names>LM</given-names></name><name><surname>Trombley</surname><given-names>J</given-names></name><name><surname>Huizinga</surname><given-names>GP</given-names></name><name><surname>Lord</surname><given-names>AE</given-names></name><name><surname>Orning</surname><given-names>P</given-names></name><name><surname>Elling</surname><given-names>R</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Olive</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A genetic screen in macrophages identifies new regulators of IFNγ-inducible MHCII that contribute to T cell activation</article-title><source>eLife</source><volume>10</volume><elocation-id>e65110</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.65110</pub-id><pub-id pub-id-type="pmid">34747695</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kledal</surname><given-names>TN</given-names></name><name><surname>Rosenkilde</surname><given-names>MM</given-names></name><name><surname>Schwartz</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28</article-title><source>FEBS Letters</source><volume>441</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(98)01551-8</pub-id><pub-id pub-id-type="pmid">9883886</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>LeDeist</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Griscelli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome</article-title><source>The Journal of Pediatrics</source><volume>123</volume><fpage>921</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1016/s0022-3476(05)80388-9</pub-id><pub-id pub-id-type="pmid">8229525</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klobuch</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>JJ</given-names></name><name><surname>van Balen</surname><given-names>P</given-names></name><name><surname>Kester</surname><given-names>MGD</given-names></name><name><surname>de Klerk</surname><given-names>W</given-names></name><name><surname>de Ru</surname><given-names>AH</given-names></name><name><surname>Pothast</surname><given-names>CR</given-names></name><name><surname>Jedema</surname><given-names>I</given-names></name><name><surname>Drijfhout</surname><given-names>JW</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>HH</given-names></name><name><surname>van Veelen</surname><given-names>PA</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human T cells recognize HLA-DP-bound peptides in two orientations</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2214331119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2214331119</pub-id><pub-id pub-id-type="pmid">36442096</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>BA</given-names></name><name><surname>Poole</surname><given-names>EL</given-names></name><name><surname>Jackson</surname><given-names>SE</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name><name><surname>Wills</surname><given-names>MR</given-names></name><name><surname>Sinclair</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection</article-title><source>mBio</source><volume>8</volume><elocation-id>01754-17</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.01754-17</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>BA</given-names></name><name><surname>Spiess</surname><given-names>K</given-names></name><name><surname>Poole</surname><given-names>EL</given-names></name><name><surname>Lau</surname><given-names>B</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Kledal</surname><given-names>TN</given-names></name><name><surname>Rosenkilde</surname><given-names>MM</given-names></name><name><surname>Sinclair</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>14321</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms14321</pub-id><pub-id pub-id-type="pmid">28148951</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>BA</given-names></name><name><surname>Miller</surname><given-names>WE</given-names></name><name><surname>O’Connor</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>US28: HCMV’s swiss army knife</article-title><source>Viruses</source><volume>10</volume><elocation-id>445</elocation-id><pub-id pub-id-type="doi">10.3390/v10080445</pub-id><pub-id pub-id-type="pmid">30127279</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishna</surname><given-names>BA</given-names></name><name><surname>Humby</surname><given-names>MS</given-names></name><name><surname>Miller</surname><given-names>WE</given-names></name><name><surname>O’Connor</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human cytomegalovirus G protein-coupled receptor US28 promotes latency by attenuating c-fos</article-title><source>PNAS</source><volume>116</volume><fpage>1755</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1073/pnas.1816933116</pub-id><pub-id pub-id-type="pmid">30647114</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>V</given-names></name><name><surname>Böhme</surname><given-names>I</given-names></name><name><surname>Hofmann</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>K</given-names></name><name><surname>Sauter</surname><given-names>J</given-names></name><name><surname>Schöne</surname><given-names>B</given-names></name><name><surname>Paul</surname><given-names>P</given-names></name><name><surname>Albrecht</surname><given-names>V</given-names></name><name><surname>Andreas</surname><given-names>JM</given-names></name><name><surname>Baier</surname><given-names>DM</given-names></name><name><surname>Nething</surname><given-names>J</given-names></name><name><surname>Ehninger</surname><given-names>U</given-names></name><name><surname>Schwarzelt</surname><given-names>C</given-names></name><name><surname>Pingel</surname><given-names>J</given-names></name><name><surname>Ehninger</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing</article-title><source>BMC Genomics</source><volume>15</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-15-63</pub-id><pub-id pub-id-type="pmid">24460756</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>VTK</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name><name><surname>Wilborn</surname><given-names>M</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Zimmermann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation</article-title><source>The Journal of General Virology</source><volume>89</volume><fpage>2416</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/001669-0</pub-id><pub-id pub-id-type="pmid">18796709</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>VTK</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb’-encoded modulation of TNF-α signaling</article-title><source>Journal of Virology</source><volume>85</volume><fpage>13260</fpage><lpage>13270</lpage><pub-id pub-id-type="doi">10.1128/JVI.06005-11</pub-id><pub-id pub-id-type="pmid">21976655</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Hornell</surname><given-names>TMC</given-names></name><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>Deshpande</surname><given-names>C</given-names></name><name><surname>Hertel</surname><given-names>L</given-names></name><name><surname>Lacaille</surname><given-names>V</given-names></name><name><surname>Pashine</surname><given-names>A</given-names></name><name><surname>Macaubas</surname><given-names>C</given-names></name><name><surname>Mocarski</surname><given-names>ES</given-names></name><name><surname>Mellins</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels</article-title><source>Molecular Immunology</source><volume>48</volume><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2011.02.010</pub-id><pub-id pub-id-type="pmid">21458073</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>N</given-names></name><name><surname>Weijer</surname><given-names>K</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Experimental models to study development and function of the human immune system in vivo</article-title><source>Journal of Immunology</source><volume>176</volume><fpage>2053</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.4.2053</pub-id><pub-id pub-id-type="pmid">16455958</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Trilling</surname><given-names>VTK</given-names></name><name><surname>Megger</surname><given-names>DA</given-names></name><name><surname>Katschinski</surname><given-names>B</given-names></name><name><surname>Landsberg</surname><given-names>CD</given-names></name><name><surname>Rückborn</surname><given-names>MU</given-names></name><name><surname>Tao</surname><given-names>S</given-names></name><name><surname>Krawczyk</surname><given-names>A</given-names></name><name><surname>Bayer</surname><given-names>W</given-names></name><name><surname>Drexler</surname><given-names>I</given-names></name><name><surname>Tenbusch</surname><given-names>M</given-names></name><name><surname>Sitek</surname><given-names>B</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Broad and potent antiviral activity of the NAE inhibitor MLN4924</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>19977</elocation-id><pub-id pub-id-type="doi">10.1038/srep19977</pub-id><pub-id pub-id-type="pmid">26829401</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Trilling</surname><given-names>VTK</given-names></name><name><surname>Wohlgemuth</surname><given-names>K</given-names></name><name><surname>Rückborn</surname><given-names>MU</given-names></name><name><surname>Jagnjic</surname><given-names>A</given-names></name><name><surname>Maaßen</surname><given-names>F</given-names></name><name><surname>Timmer</surname><given-names>L</given-names></name><name><surname>Katschinski</surname><given-names>B</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>STAT2-Dependent immune responses ensure host survival despite the presence of a potent viral antagonist</article-title><source>Journal of Virology</source><volume>92</volume><elocation-id>00296-18</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.00296-18</pub-id><pub-id pub-id-type="pmid">29743368</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Trilling</surname><given-names>VTK</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Nachshon</surname><given-names>A</given-names></name><name><surname>Stern-Ginossar</surname><given-names>N</given-names></name><name><surname>Schöler</surname><given-names>L</given-names></name><name><surname>Voigt</surname><given-names>S</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The human cytomegalovirus pUL145 isoforms act as viral DDB1-cullin-associated factors to instruct host protein degradation to impede innate immunity</article-title><source>Cell Reports</source><volume>30</volume><fpage>2248</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.01.070</pub-id><pub-id pub-id-type="pmid">32075763</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>EY</given-names></name><name><surname>Jackson</surname><given-names>SE</given-names></name><name><surname>Wills</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The CD4+ T cell response to human cytomegalovirus in healthy and immunocompromised people</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>10</volume><elocation-id>202</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00202</pub-id><pub-id pub-id-type="pmid">32509591</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>GM</given-names></name><name><surname>Jackson</surname><given-names>S</given-names></name><name><surname>Okecha</surname><given-names>G</given-names></name><name><surname>Poole</surname><given-names>E</given-names></name><name><surname>Sissons</surname><given-names>JGP</given-names></name><name><surname>Sinclair</surname><given-names>J</given-names></name><name><surname>Wills</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4(+) T cells</article-title><source>PLOS Pathogens</source><volume>9</volume><elocation-id>e1003635</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003635</pub-id><pub-id pub-id-type="pmid">24130479</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maussang</surname><given-names>D</given-names></name><name><surname>Verzijl</surname><given-names>D</given-names></name><name><surname>van Walsum</surname><given-names>M</given-names></name><name><surname>Leurs</surname><given-names>R</given-names></name><name><surname>Holl</surname><given-names>J</given-names></name><name><surname>Pleskoff</surname><given-names>O</given-names></name><name><surname>Michel</surname><given-names>D</given-names></name><name><surname>van Dongen</surname><given-names>GAMS</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis</article-title><source>PNAS</source><volume>103</volume><fpage>13068</fpage><lpage>13073</lpage><pub-id pub-id-type="doi">10.1073/pnas.0604433103</pub-id><pub-id pub-id-type="pmid">16924106</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megger</surname><given-names>DA</given-names></name><name><surname>Philipp</surname><given-names>J</given-names></name><name><surname>Le Trilling</surname><given-names>VTK</given-names></name><name><surname>Sitek</surname><given-names>B</given-names></name><name><surname>Trilling</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Deciphering of the human interferon-regulated proteome by mass spectrometry-based quantitative analysis reveals extent and dynamics of protein induction and repression</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1139</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01139</pub-id><pub-id pub-id-type="pmid">28959263</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>G</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Patkaniowska</surname><given-names>A</given-names></name><name><surname>Dorsett</surname><given-names>Y</given-names></name><name><surname>Teng</surname><given-names>G</given-names></name><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs</article-title><source>Molecular Cell</source><volume>15</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.07.007</pub-id><pub-id pub-id-type="pmid">15260970</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnychuk</surname><given-names>RM</given-names></name><name><surname>Streblow</surname><given-names>DN</given-names></name><name><surname>Smith</surname><given-names>PP</given-names></name><name><surname>Hirsch</surname><given-names>AJ</given-names></name><name><surname>Pancheva</surname><given-names>D</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Human cytomegalovirus-encoded G protein-coupled receptor US28 mediates smooth muscle cell migration through Galpha12</article-title><source>Journal of Virology</source><volume>78</volume><fpage>8382</fpage><lpage>8391</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.15.8382-8391.2004</pub-id><pub-id pub-id-type="pmid">15254210</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meurer</surname><given-names>T</given-names></name><name><surname>Arrieta-Bolaños</surname><given-names>E</given-names></name><name><surname>Metzing</surname><given-names>M</given-names></name><name><surname>Langer</surname><given-names>M-M</given-names></name><name><surname>van Balen</surname><given-names>P</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Beelen</surname><given-names>DW</given-names></name><name><surname>Horn</surname><given-names>PA</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name><name><surname>Crivello</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dissecting genetic control of HLA-DPB1 expression and its relation to structural mismatch models in hematopoietic stem cell transplantation</article-title><source>Frontiers in Immunology</source><volume>9</volume><elocation-id>2236</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02236</pub-id><pub-id pub-id-type="pmid">30344521</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meurer</surname><given-names>T</given-names></name><name><surname>Crivello</surname><given-names>P</given-names></name><name><surname>Metzing</surname><given-names>M</given-names></name><name><surname>Kester</surname><given-names>M</given-names></name><name><surname>Megger</surname><given-names>DA</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>van Veelen</surname><given-names>PA</given-names></name><name><surname>van Balen</surname><given-names>P</given-names></name><name><surname>Westendorf</surname><given-names>AM</given-names></name><name><surname>Homa</surname><given-names>G</given-names></name><name><surname>Layer</surname><given-names>SE</given-names></name><name><surname>Turki</surname><given-names>AT</given-names></name><name><surname>Griffioen</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>PA</given-names></name><name><surname>Sitek</surname><given-names>B</given-names></name><name><surname>Beelen</surname><given-names>DW</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name><name><surname>Arrieta-Bolaños</surname><given-names>E</given-names></name><name><surname>Fleischhauer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM</article-title><source>Blood</source><volume>137</volume><fpage>923</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1182/blood.2020008464</pub-id><pub-id pub-id-type="pmid">33025005</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DM</given-names></name><name><surname>Rahill</surname><given-names>BM</given-names></name><name><surname>Boss</surname><given-names>JM</given-names></name><name><surname>Lairmore</surname><given-names>MD</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Waldman</surname><given-names>JW</given-names></name><name><surname>Sedmak</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway</article-title><source>The Journal of Experimental Medicine</source><volume>187</volume><fpage>675</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1084/jem.187.5.675</pub-id><pub-id pub-id-type="pmid">9480977</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>Y</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>A</given-names></name><name><surname>Murai</surname><given-names>M</given-names></name><name><surname>Mita</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Takamura</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells</article-title><source>British Journal of Cancer</source><volume>90</volume><fpage>844</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601602</pub-id><pub-id pub-id-type="pmid">14970863</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odeberg</surname><given-names>J</given-names></name><name><surname>Plachter</surname><given-names>B</given-names></name><name><surname>Brandén</surname><given-names>L</given-names></name><name><surname>Söderberg-Nauclér</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain</article-title><source>Blood</source><volume>101</volume><fpage>4870</fpage><lpage>4877</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-05-1504</pub-id><pub-id pub-id-type="pmid">12609847</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picker</surname><given-names>LJ</given-names></name><name><surname>Lifson</surname><given-names>JD</given-names></name><name><surname>Gale</surname><given-names>M</given-names><suffix>Jr</suffix></name><name><surname>Hansen</surname><given-names>SG</given-names></name><name><surname>Früh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Programming cytomegalovirus as an HIV vaccine</article-title><source>Trends in Immunology</source><volume>44</volume><fpage>287</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.it.2023.02.001</pub-id><pub-id pub-id-type="pmid">36894436</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pleskoff</surname><given-names>O</given-names></name><name><surname>Tréboute</surname><given-names>C</given-names></name><name><surname>Brelot</surname><given-names>A</given-names></name><name><surname>Heveker</surname><given-names>N</given-names></name><name><surname>Seman</surname><given-names>M</given-names></name><name><surname>Alizon</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry</article-title><source>Science</source><volume>276</volume><fpage>1874</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1126/science.276.5320.1874</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polić</surname><given-names>B</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Krmpotić</surname><given-names>A</given-names></name><name><surname>Trgovcich</surname><given-names>J</given-names></name><name><surname>Pavić</surname><given-names>I</given-names></name><name><surname>Luccaronin</surname><given-names>P</given-names></name><name><surname>Jonjić</surname><given-names>S</given-names></name><name><surname>Koszinowski</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection</article-title><source>The Journal of Experimental Medicine</source><volume>188</volume><fpage>1047</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1084/jem.188.6.1047</pub-id><pub-id pub-id-type="pmid">9743523</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutten</surname><given-names>CE</given-names></name><name><surname>van Luxemburg-Heijs</surname><given-names>SAP</given-names></name><name><surname>van der Meijden</surname><given-names>ED</given-names></name><name><surname>Griffioen</surname><given-names>M</given-names></name><name><surname>Oudshoorn</surname><given-names>M</given-names></name><name><surname>Willemze</surname><given-names>R</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1-specific CD4+ T cell responses showing immunogenicity of all HLA-DPB1 Alleles</article-title><source>Biology of Blood and Marrow Transplantation</source><volume>16</volume><fpage>1282</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2010.03.018</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salsman</surname><given-names>J</given-names></name><name><surname>Zimmerman</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Domagala</surname><given-names>M</given-names></name><name><surname>Frappier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genome-wide screen of three herpesviruses for protein subcellular localization and alteration of PML nuclear bodies</article-title><source>PLOS Pathogens</source><volume>4</volume><elocation-id>e1000100</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000100</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>PK</given-names></name><name><surname>Buchkovich</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Human cytomegalovirus decreases major histocompatibility complex Class II by regulating Class II transactivator transcript levels in a myeloid cell line</article-title><source>Journal of Virology</source><volume>94</volume><elocation-id>e01901-19</elocation-id><pub-id pub-id-type="doi">10.1128/JVI.01901-19</pub-id><pub-id pub-id-type="pmid">31915281</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnappauf</surname><given-names>F</given-names></name><name><surname>Hake</surname><given-names>SB</given-names></name><name><surname>Camacho Carvajal</surname><given-names>MM</given-names></name><name><surname>Bontron</surname><given-names>S</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>Steimle</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA</article-title><source>European Journal of Immunology</source><volume>33</volume><fpage>2337</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1002/eji.200323490</pub-id><pub-id pub-id-type="pmid">12884309</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>JW</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Panis</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>MY</given-names></name><name><surname>Jones</surname><given-names>CT</given-names></name><name><surname>Bieniasz</surname><given-names>P</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title><source>Nature</source><volume>472</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/nature09907</pub-id><pub-id pub-id-type="pmid">21478870</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidel</surname><given-names>E</given-names></name><name><surname>Le</surname><given-names>VTK</given-names></name><name><surname>Bar-On</surname><given-names>Y</given-names></name><name><surname>Tsukerman</surname><given-names>P</given-names></name><name><surname>Enk</surname><given-names>J</given-names></name><name><surname>Yamin</surname><given-names>R</given-names></name><name><surname>Stein</surname><given-names>N</given-names></name><name><surname>Schmiedel</surname><given-names>D</given-names></name><name><surname>Oiknine Djian</surname><given-names>E</given-names></name><name><surname>Weisblum</surname><given-names>Y</given-names></name><name><surname>Tirosh</surname><given-names>B</given-names></name><name><surname>Stastny</surname><given-names>P</given-names></name><name><surname>Wolf</surname><given-names>DG</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Mandelboim</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dynamic co-evolution of host and pathogen: HCMV downregulates the prevalent allele MICA∗008 to escape elimination by NK cells</article-title><source>Cell Reports</source><volume>10</volume><fpage>968</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.029</pub-id><pub-id pub-id-type="pmid">25683719</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shnayder</surname><given-names>M</given-names></name><name><surname>Nachshon</surname><given-names>A</given-names></name><name><surname>Rozman</surname><given-names>B</given-names></name><name><surname>Bernshtein</surname><given-names>B</given-names></name><name><surname>Lavi</surname><given-names>M</given-names></name><name><surname>Fein</surname><given-names>N</given-names></name><name><surname>Poole</surname><given-names>E</given-names></name><name><surname>Avdic</surname><given-names>S</given-names></name><name><surname>Blyth</surname><given-names>E</given-names></name><name><surname>Gottlieb</surname><given-names>D</given-names></name><name><surname>Abendroth</surname><given-names>A</given-names></name><name><surname>Slobedman</surname><given-names>B</given-names></name><name><surname>Sinclair</surname><given-names>J</given-names></name><name><surname>Stern-Ginossar</surname><given-names>N</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single cell analysis reveals human cytomegalovirus drives latently infected cells towards an anergic-like monocyte state</article-title><source>eLife</source><volume>9</volume><elocation-id>e52168</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.52168</pub-id><pub-id pub-id-type="pmid">31967545</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Martinez-Soria</surname><given-names>E</given-names></name><name><surname>Kern</surname><given-names>I</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma</article-title><source>The Journal of Experimental Medicine</source><volume>182</volume><fpage>1793</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1084/jem.182.6.1793</pub-id><pub-id pub-id-type="pmid">7500024</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slinger</surname><given-names>E</given-names></name><name><surname>Maussang</surname><given-names>D</given-names></name><name><surname>Schreiber</surname><given-names>A</given-names></name><name><surname>Siderius</surname><given-names>M</given-names></name><name><surname>Rahbar</surname><given-names>A</given-names></name><name><surname>Fraile-Ramos</surname><given-names>A</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Söderberg-Nauclér</surname><given-names>C</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>ra58</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2001180</pub-id><pub-id pub-id-type="pmid">20682912</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slobedman</surname><given-names>B</given-names></name><name><surname>Mocarski</surname><given-names>ES</given-names></name><name><surname>Arvin</surname><given-names>AM</given-names></name><name><surname>Mellins</surname><given-names>ED</given-names></name><name><surname>Abendroth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors</article-title><source>Blood</source><volume>100</volume><fpage>2867</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1182/blood.V100.8.2867</pub-id><pub-id pub-id-type="pmid">12351397</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Otten</surname><given-names>LA</given-names></name><name><surname>Zufferey</surname><given-names>M</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)</article-title><source>Cell</source><volume>75</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">8402893</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevanovic</surname><given-names>S</given-names></name><name><surname>van Bergen</surname><given-names>CAM</given-names></name><name><surname>van Luxemburg-Heijs</surname><given-names>SAP</given-names></name><name><surname>van der Zouwen</surname><given-names>B</given-names></name><name><surname>Jordanova</surname><given-names>ES</given-names></name><name><surname>Kruisselbrink</surname><given-names>AB</given-names></name><name><surname>van de Meent</surname><given-names>M</given-names></name><name><surname>Harskamp</surname><given-names>JC</given-names></name><name><surname>Claas</surname><given-names>FHJ</given-names></name><name><surname>Marijt</surname><given-names>EWA</given-names></name><name><surname>Zwaginga</surname><given-names>JJ</given-names></name><name><surname>Halkes</surname><given-names>CJM</given-names></name><name><surname>Jedema</surname><given-names>I</given-names></name><name><surname>Griffioen</surname><given-names>M</given-names></name><name><surname>Falkenburg</surname><given-names>JHF</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion</article-title><source>Blood</source><volume>122</volume><fpage>1963</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-470872</pub-id><pub-id pub-id-type="pmid">23777765</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streblow</surname><given-names>DN</given-names></name><name><surname>Soderberg-Naucler</surname><given-names>C</given-names></name><name><surname>Vieira</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Wakabayashi</surname><given-names>E</given-names></name><name><surname>Ruchti</surname><given-names>F</given-names></name><name><surname>Mattison</surname><given-names>K</given-names></name><name><surname>Altschuler</surname><given-names>Y</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration</article-title><source>Cell</source><volume>99</volume><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81539-1</pub-id><pub-id pub-id-type="pmid">10589679</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Streblow</surname><given-names>DN</given-names></name><name><surname>Vomaske</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><name><surname>Melnychuk</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>L</given-names></name><name><surname>Pancheva</surname><given-names>D</given-names></name><name><surname>Smit</surname><given-names>M</given-names></name><name><surname>Casarosa</surname><given-names>P</given-names></name><name><surname>Schlaepfer</surname><given-names>DD</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>50456</fpage><lpage>50465</lpage><pub-id pub-id-type="doi">10.1074/jbc.M307936200</pub-id><pub-id pub-id-type="pmid">14506272</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobl</surname><given-names>B</given-names></name><name><surname>Bubic</surname><given-names>I</given-names></name><name><surname>Bruns</surname><given-names>U</given-names></name><name><surname>Steinborn</surname><given-names>R</given-names></name><name><surname>Lajko</surname><given-names>R</given-names></name><name><surname>Kolbe</surname><given-names>T</given-names></name><name><surname>Karaghiosoff</surname><given-names>M</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Jonjic</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus</article-title><source>Journal of Immunology</source><volume>175</volume><fpage>4000</fpage><lpage>4008</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.6.4000</pub-id><pub-id pub-id-type="pmid">16148148</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>JPY</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Genetic control of MHC class II expression</article-title><source>Cell</source><volume>109 Suppl</volume><fpage>S21</fpage><lpage>S33</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00696-7</pub-id><pub-id pub-id-type="pmid">11983150</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tischer</surname><given-names>BK</given-names></name><name><surname>von Einem</surname><given-names>J</given-names></name><name><surname>Kaufer</surname><given-names>B</given-names></name><name><surname>Osterrieder</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in <italic>Escherichia coli</italic></article-title><source>BioTechniques</source><volume>40</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.2144/000112096</pub-id><pub-id pub-id-type="pmid">16526409</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomazin</surname><given-names>R</given-names></name><name><surname>Boname</surname><given-names>J</given-names></name><name><surname>Hegde</surname><given-names>NR</given-names></name><name><surname>Lewinsohn</surname><given-names>DM</given-names></name><name><surname>Altschuler</surname><given-names>Y</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Cresswell</surname><given-names>P</given-names></name><name><surname>Nelson</surname><given-names>JA</given-names></name><name><surname>Riddell</surname><given-names>SR</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells</article-title><source>Nature Medicine</source><volume>5</volume><fpage>1039</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1038/12478</pub-id><pub-id pub-id-type="pmid">10470081</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trilling</surname><given-names>M</given-names></name><name><surname>Le</surname><given-names>VTK</given-names></name><name><surname>Zimmermann</surname><given-names>A</given-names></name><name><surname>Ludwig</surname><given-names>H</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Sutter</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>GL</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts</article-title><source>Journal of Virology</source><volume>83</volume><fpage>3684</fpage><lpage>3695</lpage><pub-id pub-id-type="doi">10.1128/JVI.02042-08</pub-id><pub-id pub-id-type="pmid">19211768</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trilling</surname><given-names>M</given-names></name><name><surname>Bellora</surname><given-names>N</given-names></name><name><surname>Rutkowski</surname><given-names>AJ</given-names></name><name><surname>de Graaf</surname><given-names>M</given-names></name><name><surname>Dickinson</surname><given-names>P</given-names></name><name><surname>Robertson</surname><given-names>K</given-names></name><name><surname>Prazeres da Costa</surname><given-names>O</given-names></name><name><surname>Ghazal</surname><given-names>P</given-names></name><name><surname>Friedel</surname><given-names>CC</given-names></name><name><surname>Albà</surname><given-names>MM</given-names></name><name><surname>Dölken</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Deciphering the modulation of gene expression by type I and II interferons combining 4sU-tagging, translational arrest and in silico promoter analysis</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>8107</fpage><lpage>8125</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt589</pub-id><pub-id pub-id-type="pmid">23832230</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>EMM</given-names></name><name><surname>Remmerswaal</surname><given-names>EBM</given-names></name><name><surname>Vossen</surname><given-names>MTM</given-names></name><name><surname>Rowshani</surname><given-names>AT</given-names></name><name><surname>Wertheim-van Dillen</surname><given-names>PME</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name><name><surname>ten Berge</surname><given-names>IJM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>1834</fpage><lpage>1841</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.3.1834</pub-id><pub-id pub-id-type="pmid">15265915</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>EMM</given-names></name><name><surname>Remmerswaal</surname><given-names>EBM</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name><name><surname>ten Berge</surname><given-names>IJM</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection</article-title><source>Blood</source><volume>108</volume><fpage>3121</fpage><lpage>3127</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-03-006809</pub-id><pub-id pub-id-type="pmid">16840731</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>C</given-names></name><name><surname>Bisceglia</surname><given-names>H</given-names></name><name><surname>Girerd-Chambaz</surname><given-names>Y</given-names></name><name><surname>Burdin</surname><given-names>N</given-names></name><name><surname>Chaux</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals</article-title><source>Journal of Clinical Immunology</source><volume>32</volume><fpage>1305</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1007/s10875-012-9732-x</pub-id><pub-id pub-id-type="pmid">22797815</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Weiskopf</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>McDonald</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name><name><surname>Benedict</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cytomegalovirus-specific CD4 T cells are cytolytic and mediate vaccine protection</article-title><source>Journal of Virology</source><volume>90</volume><fpage>650</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1128/JVI.02123-15</pub-id><pub-id pub-id-type="pmid">26491148</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Gutermann</surname><given-names>A</given-names></name><name><surname>Podlech</surname><given-names>J</given-names></name><name><surname>Reddehase</surname><given-names>MJ</given-names></name><name><surname>Koszinowski</surname><given-names>UH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Major histocompatibility complex class I allele-specific cooperative and competitive interactions between immune evasion proteins of cytomegalovirus</article-title><source>The Journal of Experimental Medicine</source><volume>196</volume><fpage>805</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1084/jem.20020811</pub-id><pub-id pub-id-type="pmid">12235213</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldhoer</surname><given-names>M</given-names></name><name><surname>Casarosa</surname><given-names>P</given-names></name><name><surname>Rosenkilde</surname><given-names>MM</given-names></name><name><surname>Smit</surname><given-names>MJ</given-names></name><name><surname>Leurs</surname><given-names>R</given-names></name><name><surname>Whistler</surname><given-names>JL</given-names></name><name><surname>Schwartz</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>19473</fpage><lpage>19482</lpage><pub-id pub-id-type="doi">10.1074/jbc.M213179200</pub-id><pub-id pub-id-type="pmid">12646575</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walton</surname><given-names>SM</given-names></name><name><surname>Wyrsch</surname><given-names>P</given-names></name><name><surname>Munks</surname><given-names>MW</given-names></name><name><surname>Zimmermann</surname><given-names>A</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Hill</surname><given-names>AB</given-names></name><name><surname>Oxenius</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection</article-title><source>Journal of Immunology</source><volume>181</volume><fpage>1128</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.2.1128</pub-id><pub-id pub-id-type="pmid">18606665</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>TM</given-names></name><name><surname>Bonavita</surname><given-names>CM</given-names></name><name><surname>Stanfield</surname><given-names>BA</given-names></name><name><surname>Farrell</surname><given-names>HE</given-names></name><name><surname>Davis-Poynter</surname><given-names>NJ</given-names></name><name><surname>Cardin</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The CMV-encoded G protein-coupled receptors M33 and US28 play pleiotropic roles in immune evasion and alter host T cell responses</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>1047299</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1047299</pub-id><pub-id pub-id-type="pmid">36569845</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Anczurowski</surname><given-names>M</given-names></name><name><surname>Nakatsugawa</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Kagoya</surname><given-names>Y</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Chamoto</surname><given-names>K</given-names></name><name><surname>Ochi</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Saso</surname><given-names>K</given-names></name><name><surname>Butler</surname><given-names>MO</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>Kislinger</surname><given-names>T</given-names></name><name><surname>Hirano</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HLA-DP<sup>84Gly</sup> constitutively presents endogenous peptides generated by the class I antigen processing pathway</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15244</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15244</pub-id><pub-id pub-id-type="pmid">28489076</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunis</surname><given-names>J</given-names></name><name><surname>Farrell</surname><given-names>HE</given-names></name><name><surname>Bruce</surname><given-names>K</given-names></name><name><surname>Lawler</surname><given-names>C</given-names></name><name><surname>Sidenius</surname><given-names>S</given-names></name><name><surname>Wyer</surname><given-names>O</given-names></name><name><surname>Davis-Poynter</surname><given-names>N</given-names></name><name><surname>Stevenson</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Murine cytomegalovirus degrades MHC class II to colonize the salivary glands</article-title><source>PLOS Pathogens</source><volume>14</volume><elocation-id>e1006905</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006905</pub-id><pub-id pub-id-type="pmid">29447285</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>C</given-names></name><name><surname>Kowalewski</surname><given-names>D</given-names></name><name><surname>Bauersfeld</surname><given-names>L</given-names></name><name><surname>Hildenbrand</surname><given-names>A</given-names></name><name><surname>Gerke</surname><given-names>C</given-names></name><name><surname>Schwarzmüller</surname><given-names>M</given-names></name><name><surname>Le Trilling</surname><given-names>VTK</given-names></name><name><surname>Stevanovic</surname><given-names>S</given-names></name><name><surname>Hengel</surname><given-names>H</given-names></name><name><surname>Momburg</surname><given-names>F</given-names></name><name><surname>Halenius</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HLA-B locus products resist degradation by the human cytomegalovirus immunoevasin US11</article-title><source>PLOS Pathogens</source><volume>15</volume><elocation-id>e1008040</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008040</pub-id><pub-id pub-id-type="pmid">31527904</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96414.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brune</surname><given-names>Wolfram</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r2q1d96</institution-id><institution>Leibniz Institute of Virology (LIV)</institution></institution-wrap><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff></contrib></contrib-group></front-stub><body><p>This fundamental study substantially advances our understanding of viral immune evasion by identifying a novel player in this process and uncovering its mode of action. The evidence supporting the conclusions is compelling, with rigorous immunological assays and state-of-the-art biochemistry. The work will be of broad interest to virologists and immunologists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96414.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Brune</surname><given-names>Wolfram</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r2q1d96</institution-id><institution>Leibniz Institute of Virology (LIV)</institution></institution-wrap><addr-line><named-content content-type="city">Hamburg</named-content></addr-line><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96414.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>General Statements [optional]</p><p>We really appreciate the very insightful and thorough evaluation of our study by all three reviewers. We are grateful to the reviewers for highlighting the relevance of our work and for their suggestions on how to improve the manuscript. We addressed all comments of the reviewers – in many cases through extensive new experiments and additional data.</p><disp-quote content-type="editor-comment"><p>Reviewer #1: In this study entitled &quot;The human cytomegalovirus-encoded pUS28 antagonizes CD4<sup>+</sup> T-cell recognition by targeting CIITA&quot;, Maassen et al. tried to identify viral genes/proteins downregulating the HLA class II molecule HLA-DP. In a transfection-based screening assay, they identified US28 as a viral gene downregulating CIITA-dependent HLA-DP expression in transfected HeLa cells. Other HLA class II molecules and other proteins expressed in a CIITA-dependent manner were downregulated as well. The authors went on to show that CIITA transcripts were not reduced in the presence of pUS28, but CIITA protein levels were massively reduced, suggesting that US28 downregulates CIITA on the post-transcriptional level. A signaling-deficient US28 mutant, but not a mutant lacking the cytoplasmic carboxy terminus, was capable of reducing CIITA levels. In a final set of T cell activation experiments, the authors showed that US28-expression in HeLa cells reduced HLA-II-dependent restimulation of CD4<sup>+</sup> T cells.</p><p>The data presented in the paper are generally very clean and convincing. However, not all conclusions are sufficiently supported by the data. A major weakness of the study is the fact that most experiments were done with transfected HeLa cells. Whether the proposed US28-mediated HLA-II downregulation occurs in HCMV-infected cells remains unclear. Moreover, the proposed pUS28-CIITA interaction was demonstrated in a single co-IP experiment and the mechanism of CIITA downregulation remains obscure. Hence, the conclusion that they have identified &quot;a mechanism employed by HCMV to evade HLA-II-mediated recognition by CD4<sup>+</sup> T cells&quot; (abstract) is not justified.</p><p>Reviewer #1: Major comments: 1. The mechanism of US28-dependent CIITA downregulation remains unresolved. The authors have made several attempts to clarify the mechanism, but these experiments have not met with success. Therefore, conclusions on the underlying mechanism should be toned down or removed.</p></disp-quote><p>We identified pUS28 as an HCMV-encoded CIITA antagonist. pUS28 acts post-transcriptionally and in the absence of other viral proteins by reducing the protein half-life of CIITA. In the revised manuscript, we further show that the capacity to downregulate CIITA is evolutionary conserved in the mouse cytomegalovirus (MCMV)-encoded G protein-coupled receptor (GPCR) pM33 (see new figure 5D), and that both pUS28 and pM33 target human and mouse CIITA (see new figure 5E). Conversely, the HCMV-encoded GPCR pUS27 does not affect CIITA. We also showed that the C-Terminus of pUS28 is indispensable for CIITA degradation and HLA-II downregulation (see new Figure 7C-I), but not for the physical interaction with CIITA (see new Figure 7H), suggesting that the C-terminus connects pUS28 with the degradation machinery while the aa 1-297 contains at least one relevant domain mediating the interaction with CIITA. A panel of inhibitors did not restore CIITA (see Figure 6 —figure supplement 4).</p><p>We feel that we made several important findings regarding the mechanism of HCMV-encoded HLA-II/CD74 antagonism. Indeed, the cellular co-factors recruited by the C-terminus of pUS28 mediating CIITA degradation remain to be identified. We clearly stated this point in the revised version of the manuscript and changed the last sentence of the abstract accordingly.</p><disp-quote content-type="editor-comment"><p>Reviewer #1: 2. The claim that US28-dependent CIITA downregulation occurs by pUS28 interacting with CIITA is based on a single co-IP experiment. The result would be more convincing if the authors could show the same interaction in a reverse IP, and ideally also in HCMV-infected cells. Is the US28 C-terminus required for this interaction?</p></disp-quote><p>We agree and performed the reverse experiment (see new Figure 6A), which showed that the pUS28/CIITA complex can be precipitated by both approaches. As stated above, the C-terminus is essential for CIITA degradation and HLA-II down-regulation (Figure 7C/F/G), but not for the interaction of pUS28 with CIITA (see new Figure 7H).</p><disp-quote content-type="editor-comment"><p>Reviewer #1: 3. The authors could not demonstrate US28-dependent HLA-II downregulation in HCMV-infected cells. Hence, they cannot conclude that HCMV employs this mechanism. Transfected HeLa cells are a somewhat artificial system. This does not invalidate the data, but one has to be careful when interpreting the data. Others have shown that HCMV downregulates CIITA transcript levels in myeloid cells (PMID 21458073 and 31915281). This apparent discrepancy could either be explained by several redundant mechanisms (as proposed by the authors of this manuscript) or by differences and limitations of the respective experimental systems.</p></disp-quote><p>Based on the studies mentioned by the reviewer, which documented a down-regulation of CIITA transcript levels, and the fact that our screen argues in favor of other antagonists of CIITA-induced HLA-DR and -DP induction (see Figure 2A-C; e.g., see the effect of pUL133 and maybe pUS19), we are convinced that redundancy indeed is an important aspect of HCMV-encoded CIITA/HLA-II downregulation. The reviewer is certainly aware of the fact that HCMV encodes an astonishingly broad arsenal of partially redundant and partially cooperative antagonists with regard to various other aspects of the immune system such as HLA class I presentation and NK-cell activation (see e.g., PMID: 25418469, 31666730). We discussed this redundancy on page 12 lines 342 and following in the manuscript.</p><p>To validate our findings in a system that does not rely on transient transfection, we generated doxycycline-inducible HeLa TRex Flip-in cell clones either expressing pUS28 or pUS27. Also in this model, pUS28 – but not pUS27- significantly down-regulated HLA-DP surface levels (see new Figure 5A).</p><p>Since we agree with the reviewer regarding the importance of a loss-of-function in the HCMV infection context, we generated wt and US28-deficient HCMV mutants by BACmid mutagenesis on a <italic>UL131</italic>/pentamer-repaired, <italic>ULb</italic>’-positive HCMV-AD169-BAC2 background (the non-repaired HCMV-AD169-BAC2 parental BACmid had been sequenced, annotated and described in PMID: 32075763 and its sequence is online available as MN900952) and compared them on cells that constitutively express HLA-II on their surface. In this setup, there is no need to induce the CIITA expression and HLA-II up-regulation by IFNγ, which is susceptible to HCMV-encoded IFN antagonists (please also see our responses to your THP-1 suggestion below). In this setting, we indeed observed an US28-dependent downregulation of HLA-DP (see new figure 5B) and HLA-DR (see new figure 5C) in the HCMV infection context.</p><disp-quote content-type="editor-comment"><p>Reviewer #1: 4. The possibility that US28 might downregulate CIITA in latently infected cells is intriguing. Have the authors tested this in an HCMV latency system, e.g. in infected THP-1 or Kasumi-3 cells? I acknowledge that such experiments are not trivial and may be beyond the scope of the present study. However, as latently infected cells express US28 but not the other viral genes previously shown to affect HLA-II expression (US2, US3, IE1 and 2), the latency model might a way to demonstrate biological significance in virus-infected cells.</p></disp-quote><p>Without an assessment of CIITA, others showed a pUS28-mediated downregulation of HLA-II mRNAs and proteins in THP-1 cells (PMID: 31796538). We cited this paper (page 11 lines 319 and following). Furthermore, Shnayder <italic>et al.</italic> showed a transcriptional downregulation of different HLA-II genes and CD74 in latently infected CD14+ monocytes, which we also cited in the revised manuscript (page 12 line 333). Our data provide an explanation for these important observations.</p><p>As suggested by the reviewer, we assessed THP-1 cells with regard to an HCMV-mediated downregulation of HLA-II. In our hands, THP-1 cells did not show a constitutive HLA-II expression. As expected, we were able to induce HLA-DP and HLA-DR in THP-1 cells by IFNγ. We also observed an inhibition of IFNγ-induced HLA-DP/-DR upregulation upon HCMV infection. However, this effect was not impaired when an US28-deficient HCMV was studied (see data in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> which combines different attempts using different IFN treatment durations and infection times). We attribute this US28-independent inhibition of IFN-induced HLA-II upregulation to the HCMV-encoded IFN antagonists (discussed in the revised manuscript).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>THP-I cells were either mock infected or were infected (MOI 3) with AD169-BAC2UL131rep (wt HCMV) or AD196-BAC-UL131repΔUS28 (HCMV ΔUS28).</title><p>cells were either pre-treated with 200 IU/ml IFNγ for 24 — 48 h (different experiments) or were treated at 2 h post-infection. At 24 – 72 h post-infection (different experiments), cells were stained with anti-HLA-DP antibodies and analyzed by flow cytometry. The mean fluorescence intensity (fold MFI over background) values of HLA-II expression are depicted (n = 4-5).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96414-sa2-fig1-v1.tif"/></fig><p>THP-I cells were either mock infected or were infected (MOI 3) with AD169-BAC2UL131rep (wt HCMV) or AD196-BAC-UL131rePAUS28 (HCMV AUS28). cells were either pre-treated with 200 IJ/ml IFNγ for 24 — 48 h (different experiments) or were treated at 2 h post-infection. At 24 – 72 h post-infection (different experiments), cells were stained with anti-HLA-DP antibodies and analyzed by flow cytometry. The mean fluorescence intensity (fold MFI over background) values of HLA-II expression are depicted (n = 4-5).</p><p>The viral gene expression kinetics in Kasumi-3 are rather complex, including a phase of immediate early (IE) expression (PMID: 33731453) and according to the authors of the study “there was no preferential expression of UL138, US28, or RNA2.7 over the lytic gene UL32 when latency was established” (PMID: 30206173, 33731453). Therefore, we have refrained from applying Kasumi-3 cells as latency model.</p><p>As mentioned above, we used other cells (UoC-B6) that express HLA-II in the absence of IFNγ treatment. In this model, we observed an HCMV- and US28-dependent HLA-DP/-DR downregulation (see new figure 5B/C).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance (Required)): Recognition of virus-infected cells by CD4<sup>+</sup> T cells is an important immune defense mechanism. Viruses like HCMV have evolved numerous immune evasion mechanisms. Previous studies have identified HCMV proteins targeting HLA-II for degradation (US2, US3) or downregulating CIITA transcription (probably IE1+IE2). The findings of the present manuscript now demonstrate that US28 is capable of contributing to HLA-II downregulation. This is potentially of great significance as US28 is expressed in latently infected cells. However, the significance of the present study is limited by the fact that the studies were done in transfected HeLa cells, not in HCMV-infected cells, and that the mechanism of CIITA post-transcriptional downregulation remains unknown. In its present form, the study should be of interest for virologists and immunologists interested in new viral immune evasion strategies. The significance and appeal to a wider audience would be massively increased if the authors could clarify the mechanism or show its importance in virus-infected cells (or both).</p></disp-quote><p>As mentioned above, we confirmed the effect in another cell model (stable doxycycline-inducible cell clones [see new figure 5A]) and extended the effect to HCMV-infected cells (see new figure 5B/C). Furthermore, we show that the effect is evolutionary conserved in the MCMV homolog pM33 (see new figure 5D/E), allowing future studies in the MCMV mouse model.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Evidence, reproducibility and clarity (Required)): In this study, Maaßen and colleagues investigate how HCMV US28 functions to antagonize the class II Transactivator (CIITA) transcription factor and subsequent HLA class II expression. Through physical interaction with CIITA, US28 triggered a post-transcriptional decline in CIITA protein, leading to reduced cell surface expression of HLA class II molecules, including HLA-DR, HLA-DQ, HLA-DM, CD74, and HLA-DP. Moreover, the authors show that US28-mediated degradation of CIITA hindered the activation of HCMV-specific CD4<sup>+</sup> T cells. Strengths of this article include the rigorous methodologies and analysis, clear and concise writing, and relevance within a clinical context. Despite the strengths, a few deficiencies were identified.</p><p>Reviewer #2: There is a lack of information regarding how the expression library screen was performed and how hits were determined/chosen for further analysis.</p></disp-quote><p>In the revised manuscript, we elaborated on how the screen was performed and why we focused on pUS28 for further analyses.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 1: Lacks statistical analysis and the number of replicate experiments that were performed. Many figure legends lack the information regarding the number of replicate experiments that were performed.</p></disp-quote><p>We added this information for Figure 1 (see new Figure 1E) and throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: While the observation that US28 antagonizes CIITA is well supported, the mechanism behind the antagonism is somewhat lacking. These findings have major implications for understanding the immune response to HCMV, particularly in immunocompromised patients where impaired HLA-II presentation poses clinical risks. The authors suggest that a comprehensive understanding of the molecular mechanisms governing HCMV immune evasion could guide the development of tailored protocols for risk protection, such as vaccination, cellular therapies, or drugs targeting US28-mediated CIITA degradation.</p></disp-quote><p>Although we made additional observations regarding the molecular determinants of CIITA binding and degradation (see new Figure 7) and tested a panel of degradation inhibitors (see Figure 6 —figure supplement 4), the cellular co-factors of this degradation remain to be identified in future studies.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 2: Lacks information regarding how hits from the expression screen were determined. It would be helpful to understand the selection criteria.</p></disp-quote><p>Our criteria were a relevant inhibition of the CIITA-driven HLA-DP upregulation (assessed in the screen shown in Figure 2A), novelty (see revised text), and reproducibility (Figure 2B and data not shown). Our focus on pUS28 for further experiments is explained in the revised manuscript. A potential biological relevance of the minor effect on HLA-DP upon co-transfection of CIITA and pUS19 is currently under investigation – but beyond the scope of this manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 3: While the blots here support the authors claim that US28 antagonize CIITA at the post transcriptional level, it would be beneficial to make these observations within the context of viral infection.</p></disp-quote><p>As described in more detail in our response to Reviewer #1, we indeed confirmed the US28-dependent downregulation of HLA-DP and HLA-DR in the HCMV infection context (see new Figure 5B/C).</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 5B: Labeling of this panel is confusing. The authors should attempt to relabel, or perform the experiment again and run samples on one gel.</p></disp-quote><p>All samples were run on a single gel, blotted on one membrane, and assessed in one immunoblot. We present the results in the cropped and rearranged manner, to enable readers to directly compare corresponding time points. We have now included the uncropped immunoblot as Supplementary Figure in the revised manuscript (see new Figure 6 —figure supplement 3). We also optimized the labelling (see newly labelled Figure 6B).</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 5: data for the claim that US28-mediated antagonism of CIITA is independent of neddylation, proteasomal degradation, etc. should be shown if the authors wish to make this claim.</p></disp-quote><p>As suggested by the reviewer, we added the data of these experiments to the revised manuscript (see new Figure 6 —figure supplement 4).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Evidence, reproducibility and clarity (Required)): Maaßen and colleagues followed up on their observation that infection with HCMV mutants lacking pUS2 and 3 impaired HLA-DP expression of IFN-γ treated MRC-5 cells. This phenomenon is interesting because pUS2 and 3 are viral components that have been shown earlier to degrade HLA-DR α and HLA-DM α and thus inhibit the formation of HLA-DR α/β heterodimers. These data indicated that in addition to pUS2 and 3 some other MHC II inhibitor must be encoded by HCMV. The authors tested this hypothesis by analyzing a HCMV gene expression library for the presence of a new HLA-DP antagonist. Indeed, the data revealed pUS28 as a new MHC II inhibitor that exhibited a posttranscriptional effect on CIITA, which is the key regulator of MHC II expression. In in vitro stimulation experiments, pUS28 impaired activation of antigen-specific CD4<sup>+</sup> T cells.</p><p>The study provides new and important information on how HCMV evades human immunity. The shown data support the main conclusions. Nevertheless, inclusion of some additional controls would facilitate understanding the overall concept.</p><p>Reviewer #3: Minor points: A key element of this study is that IFN-γ induces MHC II expression on MRC-5 fibroblasts. Nevertheless, professional antigen presenting cells such as dendritic cells express MHC II independent of any stimulation. Therefore, in Figure 1 in addition to IFN-γ induced DP expression on MRC-5 fibroblasts, DP and DR expression of dendritic cells should be shown. This could be easily done by analysis of dendritic cells in PBMC. Furthermore, the authors should show DP and DR expression of dendritic cells with and without IFN-γ stimulation. Most likely, DP and DR expression of untreated dendritic cells is significantly higher than DP expression of IFN-γ treated MRC-5 cells. It is important to include such controls to avoid the impression that IFN-γ treated fibroblasts can have similar functions as professional antigen presenting cells.</p></disp-quote><p>We added the comparison (see new Figure 1 —figure supplement 1). As the reviewer anticipated, the HLA-II expression of MoDCs (even in the absence of IFNγ) exceeds the expression reached by IFNγ-exposed fibroblasts.</p><p>However, there is clear evidence that HLA/MHC-II expression occurs in cells other than DCs such as human vascular endothelial and dermal fibroblasts (PMID: 6415484, 30421030) and that the induced HLA-II expression is immunologically highly relevant. For example, a loss of an MHC-II gene (H2-Ab1) in intestinal epithelial cells (IEC) resulted in less severe DSS- and T-cell transfer-induced colitis, and 50% of mice with an IEC-specific MHC-II loss died after infection with <italic>Citrobacter rodentium</italic>, whereas none of the control mice died (PMID: 32589883). An IEC-specific deletion of MHC-II can also prevent the initiation of lethal GvHD in the GI tract (PMID: 31542340). Furthermore, monocytes and macrophages express HLA-II and can be infected by HCMV. Senescent fibroblasts also seem to express functionally relevant levels of HLA-II (PMID: 37001502). Thus, we are convinced that HCMV “has good reasons” to target the CIITA-driven inducible HLA-II expression and the recognition by IFNγ-producing CD4<sup>+</sup> T cells (Figure 9). Our observation that the MCMV-encoded GPCR pM33 also targets CIITA (see new Figure 5D/E) allows such questions to be addressed experimentally in model systems.</p><disp-quote content-type="editor-comment"><p>Reviewer #3: The conclusion in the last paragraph of the discussion that NKG2C+ memory NK cells might have activated antigen-specific CD4<sup>+</sup> T cells is confusing. In the end, professional antigen presenting cells that have taken up viral proteins most probably stimulated antigen-specific CD4<sup>+</sup> T cells. And since antigen presentation on MHC II is independent of infection of the antigen presenting cell, it is difficult to understand why under such conditions a red-queen race should have been taken place.</p></disp-quote><p>The relevance of professional antigen-presenting cells (pAPC), which remain uninfected but take up exogenous antigens and present them, is indisputable. However, we are convinced that (I) HCMV does effect cells that do express HLA-II (please see our response to the previous question) and (II) that the well-described inducibility of CIITA and the HLA-II locus by IFNγ is immunologically relevant. In accordance with this importance, we found that ability to target CIITA is evolutionary conserved in MCMV and HCMV. We favour the hypothesis that the selective pressure that led to the evolution of CMV-encoded GPCRs targeting CIITA was elicited either by HCMV-specific CD4<sup>+</sup> T cells either cytotoxic ones (PMID: 37965314, 28392788, 27606804, 17158960) or bystander T cells that upon activation produce antiviral cytokines such as IFNγ. By comparing wt-MCMV with ΔM33-MCMV infections, we will be able to test such hypotheses in the future.</p><p>We rephrased the sentence regarding the NK cells in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Description of the revisions that have already been incorporated in the transferred manuscript</p><p>Reviewer #1 6. Figure 2. The use of &quot;empty&quot; for mock-transfected cells is confusing, particularly as empty vector-transfected cells are labeled &quot;vector&quot;.</p></disp-quote><p>We changed the description in the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Many figures lack statistical analysis to support the claims made by the authors. Where applicable, the authors should include these or explicitly state that only significant comparisons are shown.</p></disp-quote><p>We added this to the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Minor Comments: Labeling for immunoblots should be clearer regarding transfection conditions. The terms &quot;empty&quot; and &quot;vector&quot; is ambiguous and is not descriptive enough for the conclusions the authors are drawing.</p></disp-quote><p>We changed the description in the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Many figures, lack statistical analysis supporting the claims being made. If observations do not reach statistical significance, these should be explicitly stated within the legends. (i.e. comparisons are shown where statically significant).</p></disp-quote><p>We added this information in the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: The authors should move away from making conclusions without showing any data substantiating their claims.</p></disp-quote><p>We added to the transferred manuscript the new Supplementary Figures that contain data previously referred to as “data not shown”.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Minor grammatical and citation errors were identified throughout the manuscript. The authors should carefully read and fix any errors prior to publication.</p></disp-quote><p>We did our best to fix the typos.</p><disp-quote content-type="editor-comment"><p>Reviewer #3: In Figure 6b the proportion of CD137-positive T cells normalized to T cells activated by HeLa cells transfected with CIITA and pulsed with HCMV lysate is shown. In this kind of data presentation, the magnitude of the original effect, i.e., the percentage of CD4<sup>+</sup> T cells that after 24 h of stimulation is CD137-positive, remains unclear. Therefore, it is recommended to first show actual data and then relative values.</p></disp-quote><p>We added the actual data as Supplementary Figure to the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3: In the figure legend it is stated n = 4-10. Does this mean that T cells from different donors of the corresponding numbers have been tested? Or have T cells from some donors been tested more than once? More precise information should be given here.</p></disp-quote><p>4-10 different donors were assessed. We added this information in the transferred manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1: Minor comments: 5. Figure 2. Why was US29 used as a control and not US27 as in other experiments. The authors pointed out themselves that US27 is probably an ideal control for US28 as both genes encode related GPCRs.</p></disp-quote><p>The experiment shown is one of the earlier experiments. At that time, we simply had not yet cloned an epitope tagged version of pUS27. The reviewer is right that pUS27 is more closely related to pUS28 than pUS29. However, the comparisons with both pUS29 and pUS27 in different experiments show that the effect elicited by pUS28 is special. We compared pUS28 with pUS27 in various other figures and there we prefer to keep the figure as is.</p><disp-quote content-type="editor-comment"><p>Reviewer #2: Figure 3: While semi-quantitative RT-PCR is a useful method for determining the levels of mRNA, it would be beneficial to conduct RT-qPCR experiments to support the claim that US28 does not affect CIITA mRNA levels.</p></disp-quote><p>We appreciate the suggestion. In our hands, qPCRs using previously described CIITA primers (used in PMID: 31915281) frequently produce a combination of a specific and an unspecific amplificate. We applied semi-quantitative RT-PCRs and separated the bands in a gel rather than performing RT-qPCRs in order to exclude that unspecific amplificates compromise our result.</p><disp-quote content-type="editor-comment"><p>Reviewer #3: Considering the higher MHC II levels expressed by dendritic cells, it would be interesting to see to which extent pUS28 expression reduces MHC II expression of dendritic cells. Such experiments can be performed by lentiviral pUS28 expression for example in monocyte-derived dendritic cells.</p></disp-quote><p>From a mechanistic point of view, this is an intriguing experimental suggestion. Obviously, HCMV-encoded antagonists can be applied as “molecular scissors” to study the pathways that they antagonize. We hope that pUS28 – like the HLA-I inhibitors in the US gene region – will also be used by others in this way. As the reviewer argued herself/himself, most of these cells will not be infected by HCMV. Therefore, we think that such experiments are simply beyond the scope of the first description of the effect.</p></body></sub-article></article>